

(A free translation of the original in Portuguese)

Raia Drogasil S.A.
Quarterly Information (ITR) at
September 30, 2018
and report on review of
quarterly information

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIÁ DROGASIL S.A.

Contents

Company information

| | |
|---------------------|---|
| Capital composition | 1 |
| Dividends | 2 |

Parent company financial information

| | |
|--|----|
| Balance sheet - assets | 3 |
| Balance sheet - liabilities and equity | 4 |
| Statement of income | 5 |
| Statement of comprehensive income | 6 |
| Statement of cash flow | 7 |
| Statement of changes in equity | |
| 1/1/2018 to 9/30/2018 | 8 |
| 1/1/2017 to 9/30/2017 | 9 |
| Statement of value added | 10 |

Consolidated financial information

| | |
|--|----|
| Balance sheet - assets | 11 |
| Balance sheet - liabilities and equity | 12 |
| Statement of income | 13 |
| Statement of comprehensive income | 14 |
| Statement of cash flow | 15 |
| Statement of changes in equity | |
| 1/1/2018 to 9/30/2018 | 16 |
| 1/1/2017 to 9/30/2017 | 17 |
| Statement of value added | 18 |

| | |
|---|----|
| Comments on company performance | 19 |
| Notes to the quarterly information | 34 |
| Comment on the behavior of business projections | 75 |

Opinions and representations

| | |
|--|----|
| Report on special review - without exceptions | 76 |
| Opinion of supervisory board or equivalent body | 78 |
| Officers' representation on financial statements | 79 |
| Officers' representation on independent auditor's report | 80 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Company information/capital composition

| Number of shares (units) | Current quarter 9/30/2018 |
|-------------------------------------|--------------------------------------|
| Paid-up share capital | |
| Common shares | 330,386,000 |
| Preferred shares | 0 |
| Total | 330,386,000 |
| Treasury shares | |
| Common shares | 1,046,572 |
| Preferred shares | 0 |
| Total | 1,046,572 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Company information/dividends

| Event | Date approved | Description | Initial date of payment | Type of share | Class of share | Amount per share (Reais/share) |
|-----------------------------|----------------------|---------------------|--------------------------------|----------------------|-----------------------|---|
| Board of Directors' Meeting | 3/21/2018 | Interest on capital | 12/3/2018 | Common | | 0.15486 |
| Board of Directors' Meeting | 6/21/2018 | Interest on capital | 12/3/2018 | Common | | 0.15334 |
| Board of Directors' Meeting | 9/21/2018 | Interest on capital | 5/31/2019 | Common | | 0.15789 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIÁ DROGASIL S.A.

Parent company financial information/balance sheet - assets

(R\$ thousand)

| Code | Description | Current quarter 9/30/2018 | Prior year 12/31/2017 |
|---------------|---|--------------------------------------|----------------------------------|
| 1 | Total assets | 6,977,479 | 6,354,767 |
| 1.01 | Current assets | 4,219,008 | 3,825,154 |
| 1.01.01 | Cash and cash equivalents | 270,396 | 255,911 |
| 1.01.03 | Trade receivables | 1,091,295 | 994,559 |
| 1.01.03.01 | Customers | 922,977 | 837,582 |
| 1.01.03.01.01 | Checks receivable | 3,038 | 3,742 |
| 1.01.03.01.02 | Credit and debit cards | 851,743 | 780,138 |
| 1.01.03.01.03 | PBM - Medicine benefit program | 46,738 | 36,600 |
| 1.01.03.01.04 | Agreements with companies | 22,678 | 20,988 |
| 1.01.03.01.05 | Bank slips/ Online transfer | 13 | 3 |
| 1.01.03.01.06 | (-) Provision for impairment of trade receivables | -1,233 | -3,889 |
| 1.01.03.02 | Other receivables | 168,318 | 156,977 |
| 1.01.03.02.01 | Advances to employees | 10,595 | 6,054 |
| 1.01.03.02.02 | Returns to suppliers | 5,270 | 6,656 |
| 1.01.03.02.03 | Commercial agreements | 105,238 | 93,550 |
| 1.01.03.02.04 | Loans receivable - subsidiaries | 36 | 38,831 |
| 1.01.03.02.05 | Other | 47,179 | 11,886 |
| 1.01.04 | Inventory | 2,756,176 | 2,478,939 |
| 1.01.04.01 | Goods for resale | 2,767,075 | 2,490,941 |
| 1.01.04.02 | Materials | 1,886 | 1,819 |
| 1.01.04.03 | (-) Allowance for losses on goods | -12,785 | -13,821 |
| 1.01.06 | Taxes recoverable | 71,959 | 78,088 |
| 1.01.06.01 | Current taxes recoverable | 71,959 | 78,088 |
| 1.01.06.01.01 | Taxes on profit | 5,074 | 654 |
| 1.01.06.01.02 | Other taxes recoverable | 66,885 | 77,434 |
| 1.01.07 | Prepaid expenses | 29,182 | 17,657 |
| 1.02 | Non-current assets | 2,758,471 | 2,529,613 |
| 1.02.01 | Long term receivables | 115,515 | 68,753 |
| 1.02.01.04 | Trade receivables | 41,953 | 1,622 |
| 1.02.01.04.02 | Other receivables | 1,285 | 1,622 |
| 1.02.01.04.03 | Loans receivable - subsidiaries | 40,668 | 0 |
| 1.02.01.08 | Prepaid expenses | 1,587 | 4,941 |
| 1.02.01.10 | Other non-current assets | 71,975 | 62,190 |
| 1.02.01.10.04 | Judicial deposits | 33,368 | 29,215 |
| 1.02.01.10.05 | Taxes recoverable | 38,607 | 32,975 |
| 1.02.02 | Investments | 34,677 | 31,489 |
| 1.02.02.01 | Equity interests | 34,677 | 31,489 |
| 1.02.02.01.02 | Interests in subsidiaries | 34,677 | 31,489 |
| 1.02.03 | Property and equipment | 1,443,760 | 1,273,913 |
| 1.02.04 | Intangible assets | 1,164,519 | 1,155,458 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIÁ DROGASIL S.A.

Parent company financial information/balance sheet - liabilities and equity

(R\$ thousand)

| Code | Description | Current quarter 9/30/2018 | Prior year 12/31/2017 |
|---------------|---|--------------------------------------|----------------------------------|
| 2 | Total liabilities and equity | 6,977,479 | 6,354,767 |
| 2.01 | Current liabilities | 2,622,495 | 2,415,001 |
| 2.01.01 | Social security and labor obligations | 283,447 | 198,835 |
| 2.01.01.01 | Social security obligations | 53,971 | 40,378 |
| 2.01.01.02 | Labor obligations | 229,476 | 158,457 |
| 2.01.02 | Trade payables | 1,774,722 | 1,745,041 |
| 2.01.02.01 | Domestic suppliers | 1,774,722 | 1,745,041 |
| 2.01.03 | Tax obligations | 77,554 | 127,247 |
| 2.01.03.01 | Federal tax obligations | 23,010 | 75,883 |
| 2.01.03.01.01 | Income tax and social contribution payable | 0 | 3,189 |
| 2.01.03.01.02 | Other federal tax obligations | 23,010 | 72,694 |
| 2.01.03.02 | State tax obligations | 50,808 | 49,318 |
| 2.01.03.03 | Municipal tax obligations | 3,736 | 2,046 |
| 2.01.04 | Borrowing | 230,797 | 196,248 |
| 2.01.04.01 | Borrowing | 100,143 | 126,741 |
| 2.01.04.01.01 | In local currency | 100,143 | 126,741 |
| 2.01.04.02 | Debentures | 130,654 | 69,507 |
| 2.01.04.02.01 | Debentures | 130,654 | 69,507 |
| 2.01.05 | Other obligations | 239,667 | 136,098 |
| 2.01.05.02 | Other | 239,667 | 136,098 |
| 2.01.05.02.01 | Dividends and interest on capital | 134,419 | 37,288 |
| 2.01.05.02.04 | Rentals | 72,658 | 65,768 |
| 2.01.05.02.06 | Other payables | 32,590 | 33,042 |
| 2.01.06 | Provision | 16,308 | 11,532 |
| 2.01.06.01 | Provision for tax, social security, labor and civil contingencies | 286 | 2,817 |
| 2.01.06.01.01 | Tax provision | 0 | 93 |
| 2.01.06.01.05 | Provision for legal claims | 286 | 2,724 |
| 2.01.06.02 | Other provisions | 16,022 | 8,715 |
| 2.01.06.02.06 | Provisions for sundry obligations | 16,022 | 8,715 |
| 2.02 | Non-current liabilities | 990,596 | 717,253 |
| 2.02.01 | Borrowing | 665,921 | 414,711 |
| 2.02.01.01 | Borrowing | 111,343 | 181,062 |
| 2.02.01.01.01 | In local currency | 111,343 | 181,062 |
| 2.02.01.02 | Debentures | 554,578 | 233,649 |
| 2.02.01.02.01 | Debentures | 554,578 | 233,649 |
| 2.02.02 | Other obligations | 63,374 | 68,156 |
| 2.02.02.02 | Other | 63,374 | 68,156 |
| 2.02.02.02.03 | Tax recovery program (REFIS) | 11,700 | 20,641 |
| 2.02.02.02.04 | Call option for additional shares | 51,674 | 47,515 |
| 2.02.03 | Deferred taxes | 254,862 | 226,217 |
| 2.02.03.01 | Deferred income tax and social contribution | 254,862 | 226,217 |
| 2.02.04 | Provision | 6,439 | 8,169 |
| 2.02.04.01 | Provision for tax, social security, labor and civil contingencies | 6,439 | 8,169 |
| 2.02.04.01.05 | Provision for legal claims | 6,439 | 8,169 |
| 2.03 | Equity | 3,364,388 | 3,222,513 |
| 2.03.01 | Paid-up share capital | 1,808,639 | 1,808,639 |
| 2.03.02 | Capital reserves | 113,518 | 151,156 |
| 2.03.04 | Revenue reserves | 1,228,149 | 1,280,751 |
| 2.03.04.01 | Legal reserve | 90,397 | 90,397 |
| 2.03.04.02 | Statutory reserve | 1,137,752 | 1,137,752 |
| 2.03.04.08 | Proposed additional dividends | 0 | 52,602 |
| 2.03.05 | Retained earnings (accumulated deficit) | 232,246 | 0 |
| 2.03.06 | Carrying value adjustments | -18,164 | -18,033 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RALA DROGASIL S.A.

Parent company financial information/statement of income

(R\$ thousand)

| Code | Description | Current quarter 7/1/2018 to 9/30/2018 | Accumulated - prior year 1/1/2018 to 9/30/2018 | Same quarter - prior year 7/1/2017 to 9/30/2017 | Accumulated - prior year 1/1/2017 to 9/30/2017 |
|-------------|--|--|---|--|---|
| 3.01 | Net sales revenue | 3,574,952 | 10,314,182 | 3,285,538 | 9,349,530 |
| 3.01.01 | Gross sales revenue | 3,744,790 | 10,802,338 | 3,437,693 | 9,798,281 |
| 3.01.02 | Taxes on sales | -139,510 | -402,115 | -123,390 | -349,223 |
| 3.01.03 | Rebates | -30,328 | -86,041 | -28,765 | -99,528 |
| 3.02 | Cost of sales and/or services | -2,476,118 | -7,115,994 | -2,279,288 | -6,449,052 |
| 3.03 | Gross profit | 1,098,834 | 3,198,188 | 1,006,250 | 2,900,478 |
| 3.04 | Operating income/expenses | -915,113 | -2,632,979 | -797,976 | -2,312,293 |
| 3.04.01 | Selling expenses | -816,171 | -2,347,747 | -709,286 | -2,048,514 |
| 3.04.02 | General and administrative expenses | -96,527 | -278,449 | -89,219 | -262,924 |
| 3.04.02.01 | Administrative expenses | -96,527 | -278,449 | -89,219 | -262,924 |
| 3.04.05 | Other operating expenses | -3,502 | -9,742 | 0 | -2,160 |
| 3.04.05.01 | Extraordinary expenses | -3,502 | -9,742 | 0 | -2,160 |
| 3.04.06 | Equity in the results of investees | 1,087 | 2,959 | 529 | 1,305 |
| 3.05 | Profit before finance results and taxes | 183,721 | 565,209 | 208,274 | 588,185 |
| 3.06 | Finance results | -26,178 | -66,640 | -28,479 | -84,670 |
| 3.06.01 | Finance income | 18,427 | 51,780 | 27,312 | 82,057 |
| 3.06.02 | Finance costs | -44,605 | -118,420 | -55,791 | -166,727 |
| 3.07 | Profit before income tax and social contribution | 157,543 | 498,569 | 179,795 | 503,515 |
| 3.08 | Income tax and social contribution | -29,596 | -113,210 | -43,735 | -126,118 |
| 3.08.01 | Current | -27,895 | -84,497 | -30,776 | -100,956 |
| 3.08.02 | Deferred | -1,701 | -28,713 | -12,959 | -25,162 |
| 3.09 | Profit (loss) from continuing operations | 127,947 | 385,359 | 136,060 | 377,397 |
| 3.11 | Profit/loss for the period | 127,947 | 385,359 | 136,060 | 377,397 |
| 3.99 | Earnings per share - (Reais/share) | | | | |
| 3.99.01 | Basic earnings per share - R\$ | | | | |
| 3.99.01.01 | Common shares | 0.38839 | 1.16978 | 0.41233 | 1.14381 |
| 3.99.02 | Diluted earnings per share - R\$ | | | | |
| 3.99.02.01 | Common shares | 0.38858 | 1.17035 | 0.41233 | 1.14369 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RALA DROGASIL S.A.

Parent company financial information/statement of comprehensive income

(R\$ thousand)

| Code | Description | Current quarter 7/1/2018 to 9/30/2018 | Accumulated - prior year 1/1/2018 to 9/30/2018 | Same quarter - prior year 7/1/2017 to 9/30/2017 | Accumulated - prior year 1/1/2017 to 9/30/2017 |
|-------------|-------------------------------------|--|---|--|---|
| 4.01 | Profit for the period | 127,947 | 385.359 | 136,060 | 377.397 |
| 4.03 | Comprehensive income for the period | 127,947 | 385.359 | 136,060 | 377.397 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Parent company financial information/statement of cash flow - indirect method

(R\$ thousand)

| Code | Description | Accumulated - current year 1/1/2018 to 9/30/2018 | Accumulated - prior year 1/1/2017 to 9/30/2017 |
|------------|--|---|---|
| 6.01 | Net cash provided by operating activities | 365,574 | 421,575 |
| 6.01.01 | Cash from operations | 846,013 | 826,968 |
| 6.01.01.01 | Profit before income tax and social contribution | 498,569 | 503,515 |
| 6.01.01.02 | Depreciation and amortization | 300,050 | 244,202 |
| 6.01.01.03 | Share-based compensation plan, net | 9,287 | 9,485 |
| 6.01.01.04 | Interest on call option for additional shares | 4,159 | 7,287 |
| 6.01.01.05 | Result on disposal of property and equipment and intangible assets | 7,272 | 4,636 |
| 6.01.01.06 | (Reversal) provision for legal claims | -3,677 | 7,866 |
| 6.01.01.07 | (Reversal) provision for inventory losses | -1,036 | 1,952 |
| 6.01.01.08 | (Reversal) provision for impairment of trade receivables | -4,124 | 1,419 |
| 6.01.01.09 | (Reversal) provision for store closures | -1,228 | -2,340 |
| 6.01.01.10 | Interest expenses | 42,583 | 50,128 |
| 6.01.01.11 | Amortization of transaction cost of debentures | -2,883 | 123 |
| 6.01.01.12 | Equity in the results of investees | -2,959 | -1,305 |
| 6.01.02 | Changes in assets and liabilities | -359,895 | -297,989 |
| 6.01.02.01 | Trade receivables and other receivables | -90,630 | -101,159 |
| 6.01.02.02 | Inventory | -276,201 | -189,805 |
| 6.01.02.03 | Other current assets | -5,396 | 19,548 |
| 6.01.02.04 | Long-term receivables | -46,764 | -15,223 |
| 6.01.02.05 | Trade payables | 25,219 | -57,662 |
| 6.01.02.06 | Salaries and social charges | 84,612 | 50,580 |
| 6.01.02.07 | Taxes and contributions | -54,955 | -8,621 |
| 6.01.02.08 | Other liabilities | -2,670 | -906 |
| 6.01.02.09 | Rentals payable | 6,890 | 5,259 |
| 6.01.03 | Other | -120,544 | -107,404 |
| 6.01.03.01 | Interest paid | -19,708 | -17,061 |
| 6.01.03.02 | Income tax and social contribution paid | -100,836 | -90,343 |
| 6.02 | Net cash used in investing activities | -482,753 | -500,694 |
| 6.02.03 | Purchases of property and equipment and intangible assets | -480,663 | -479,096 |
| 6.02.04 | Proceeds from sale of property and equipment | 10 | 603 |
| 6.02.05 | Loans granted to subsidiaries | -2,100 | -22,201 |
| 6.03 | Net cash used in financing activities | 131,664 | 186,892 |
| 6.03.01 | Borrowing | 400,587 | 373,365 |
| 6.03.02 | Repayments of borrowing | -134,820 | -101,258 |
| 6.03.03 | Repurchase of shares | -46,925 | 0 |
| 6.03.04 | Interest on capital and dividends paid | -87,178 | -85,215 |
| 6.05 | Increase (decrease) in cash and cash equivalents | 14,485 | 107,773 |
| 6.05.01 | Cash and cash equivalents at the beginning of the period | 255,911 | 273,095 |
| 6.05.02 | Cash and cash equivalents at the end of the period | 270,396 | 380,868 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIÁ DROGASIL S.A.

Parent company financial information/statement of changes in equity - 1/1/2018 to 9/30/2018

(R\$ thousand)

| Code | Description | Paid-up share capital | Capital reserves, options granted and treasury shares | Revenue reserves | Retained earnings/ accumulated deficit | Other comprehensive income | Equity |
|---------|---|-----------------------|---|------------------|--|----------------------------|-----------|
| 5.01 | Opening balance | 1,808,639 | 151,156 | 1,280,751 | 0 | -18,033 | 3,222,513 |
| 5.03 | Adjusted opening balance | 1,808,639 | 151,156 | 1,280,751 | 0 | -18,033 | 3,222,513 |
| 5.04 | Equity transactions with owners | 0 | -37,638 | -52,602 | -153,244 | 0 | -243,484 |
| 5.04.07 | Interest on capital | 0 | 0 | 0 | -153,500 | 0 | -153,500 |
| 5.04.08 | Interest on capital of 2017 approved at the AGM of March 28, 2018 | 0 | 0 | -52,602 | 0 | 0 | -52,602 |
| 5.04.09 | Interest on capital expired | 0 | 0 | 0 | 256 | 0 | 256 |
| 5.04.10 | Restricted share plan - Vesting period | 0 | 9,287 | 0 | 0 | 0 | 9,287 |
| 5.04.11 | Restricted share plan - Delivery | 0 | -7,382 | 0 | 0 | 0 | -7,382 |
| 5.04.12 | Goodwill on sale of shares | 0 | 3,115 | 0 | 0 | 0 | 3,115 |
| 5.04.13 | Treasury shares – delivery | 0 | 4,267 | 0 | 0 | 0 | 4,267 |
| 5.04.14 | Repurchase of shares | 0 | -46,925 | 0 | 0 | 0 | -46,925 |
| 5.05 | Total comprehensive income | 0 | 0 | 0 | 385,359 | 0 | 385,359 |
| 5.05.01 | Profit for the period | 0 | 0 | 0 | 385,359 | 0 | 385,359 |
| 5.06 | Internal changes in equity | 0 | 0 | 0 | 131 | -131 | 0 |
| 5.06.02 | Realization of revaluation reserve | 0 | 0 | 0 | 199 | -199 | 0 |
| 5.06.03 | Taxes on realization of revaluation reserve | 0 | 0 | 0 | -68 | 68 | 0 |
| 5.07 | Closing balance | 1,808,639 | 113,518 | 1,228,149 | 232,246 | -18,164 | 3,364,388 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Parent company financial information/statement of changes in equity - 1/1/2017 to 9/30/2017

(R\$ thousand)

| Code | Description | Paid-up share capital | Capital reserves, options granted and treasury shares | Revenue reserves | Retained earnings/ accumulated deficit | Other comprehensive income | Equity |
|-------------|---|--------------------------------------|--|-----------------------------|---|---|---------------|
| 5.01 | Opening balance | 1,808,639 | 138,553 | 980,442 | 0 | -17,847 | 2,909,787 |
| 5.03 | Adjusted opening balance | 1,808,639 | 138,553 | 980,442 | 0 | -17,847 | 2,909,787 |
| 5.04 | Equity transactions with owners | 0 | 9,486 | -61,324 | -150,918 | 0 | -202,756 |
| 5.04.07 | Interest on capital | 0 | 0 | 0 | -151,000 | 0 | -151,000 |
| 5.04.08 | Interest on capital of 2016 approved at the AGM of March 29, 2017 | 0 | 0 | -61,324 | 0 | 0 | -61,324 |
| 5.04.09 | Interest on capital expired | 0 | 0 | 0 | 82 | 0 | 82 |
| 5.04.10 | Restricted share plan - Vesting period | 0 | 9,486 | 0 | 0 | 0 | 9,486 |
| 5.04.11 | Restricted share plan - Delivery | 0 | -4,863 | 0 | 0 | 0 | -4,863 |
| 5.04.12 | Goodwill on sale of shares | 0 | 1,382 | 0 | 0 | 0 | 1,382 |
| 5.04.13 | Treasury shares – Delivery | 0 | 3,481 | 0 | 0 | 0 | 3,481 |
| 5.05 | Total comprehensive income | 0 | 0 | 0 | 377,397 | 0 | 377,397 |
| 5.05.01 | Profit for the period | 0 | 0 | 0 | 377,397 | 0 | 377,397 |
| 5.06 | Internal changes in equity | 0 | 0 | 0 | 140 | -140 | 0 |
| 5.06.02 | Realization of revaluation reserve | 0 | 0 | 0 | 212 | -212 | 0 |
| 5.06.03 | Taxes on realization of revaluation reserve | 0 | 0 | 0 | -72 | 72 | 0 |
| 5.07 | Closing balance | 1,808,639 | 148,039 | 919,118 | 226,619 | -17,987 | 3,084,428 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIÁ DROGASIL S.A.

Parent company financial information/statement of value added

(R\$ thousand)

| Code | Description | Accumulated - | Accumulated - |
|------------|---|---------------------------------------|-------------------------------------|
| | | current year 1/1/2018 to 9/30/2018 | prior year 1/1/2017 to 9/30/2017 |
| 7.01 | Revenue | 10,721,061 | 9,697,793 |
| 7.01.01 | Sales of products and services | 10,716,305 | 9,698,751 |
| 7.01.02 | Other income | 632 | 461 |
| 7.01.04 | Provision for/reversal of impairment of trade receivables | 4,124 | -1,419 |
| 7.02 | Inputs acquired from third parties | -7,096,844 | -6,366,639 |
| 7.02.01 | Cost of sales and services | -6,487,525 | -5,845,076 |
| 7.02.02 | Materials, energy, outsourced services and other | -603,300 | -518,806 |
| 7.02.03 | Impairment/recovery of assets | -6,019 | -2,757 |
| 7.03 | Gross value added | 3,624,217 | 3,331,154 |
| 7.04 | Retentions | -300,050 | -244,202 |
| 7.04.01 | Depreciation, amortization and depletion | -300,050 | -244,202 |
| 7.05 | Net value added generated by the entity | 3,324,167 | 3,086,952 |
| 7.06 | Value added received through transfer | 58,331 | 83,362 |
| 7.06.01 | Equity in the results of investees | 2,959 | 1,305 |
| 7.06.02 | Finance income | 52,374 | 82,057 |
| 7.06.03 | Other | 2,998 | 0 |
| 7.07 | Total value added to distribute | 3,382,498 | 3,170,314 |
| 7.08 | Distribution of value added | 3,382,498 | 3,170,314 |
| 7.08.01 | Personnel | 1,106,204 | 987,264 |
| 7.08.01.01 | Direct remuneration | 867,277 | 790,970 |
| 7.08.01.02 | Benefits | 162,527 | 139,277 |
| 7.08.01.03 | Unemployment compensation fund | 76,400 | 57,017 |
| 7.08.02 | Taxes and contributions | 1,339,785 | 1,289,121 |
| 7.08.02.01 | Federal | 389,593 | 371,105 |
| 7.08.02.02 | State | 933,296 | 902,912 |
| 7.08.02.03 | Municipal | 16,896 | 15,104 |
| 7.08.03 | Providers of capital | 551,150 | 516,532 |
| 7.08.03.01 | Interest | 117,073 | 165,488 |
| 7.08.03.02 | Rentals | 434,077 | 351,044 |
| 7.08.04 | Stockholders and the Company | 385,359 | 377,397 |
| 7.08.04.01 | Interest on capital | 153,500 | 151,000 |
| 7.08.04.03 | Profits reinvested/loss for the period | 231,859 | 226,397 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Consolidated financial information/balance sheet - assets

(R\$ thousand)

| Code | Description | Current quarter 9/30/2018 | Prior year 12/31/2017 |
|---------------|---|--------------------------------------|----------------------------------|
| 1 | Total assets | 7,116,260 | 6,464,249 |
| 1.01 | Current assets | 4,395,575 | 3,928,204 |
| 1.01.01 | Cash and cash equivalents | 273,555 | 264,873 |
| 1.01.03 | Trade receivables | 1,210,517 | 1,049,074 |
| 1.01.03.01 | Customers | 1,041,121 | 930,071 |
| 1.01.03.01.01 | Checks receivable | 122,598 | 97,479 |
| 1.01.03.01.02 | Credit and debit cards | 851,122 | 779,665 |
| 1.01.03.01.03 | PBM - Medicine benefit program | 46,738 | 36,600 |
| 1.01.03.01.04 | Agreements with companies | 22,678 | 20,988 |
| 1.01.03.01.05 | Bank slip/ Online transfer | 13 | 3 |
| 1.01.03.01.06 | (-) Provision for impairment of receivables | -2,028 | -4,664 |
| 1.01.03.02 | Other receivables | 169,396 | 119,003 |
| 1.01.03.02.01 | Advances to employees | 10,617 | 6,216 |
| 1.01.03.02.02 | Returns to suppliers | 5,270 | 6,656 |
| 1.01.03.02.03 | Commercial agreements | 106,258 | 94,240 |
| 1.01.03.02.05 | Other | 47,251 | 11,891 |
| 1.01.04 | Inventory | 2,806,902 | 2,517,594 |
| 1.01.04.01 | Goods for resale | 2,817,801 | 2,529,596 |
| 1.01.04.02 | Materials | 1,886 | 1,819 |
| 1.01.04.03 | (-) Provision for losses on goods | -12,785 | -13,821 |
| 1.01.06 | Taxes recoverable | 75,027 | 78,778 |
| 1.01.06.01 | Current taxes recoverable | 75,027 | 78,778 |
| 1.01.06.01.01 | Other taxes recoverable | 5,074 | 654 |
| 1.01.06.01.02 | Taxes on profit | 69,953 | 78,124 |
| 1.01.07 | Prepaid expenses | 29,574 | 17,885 |
| 1.02 | Non-current assets | 2,720,685 | 2,536,045 |
| 1.02.01 | Long-term receivables | 74,847 | 68,753 |
| 1.02.01.04 | Trade receivables | 1,285 | 1,622 |
| 1.02.01.04.02 | Other receivables | 1,285 | 1,622 |
| 1.02.01.08 | Prepaid expenses | 1,587 | 4,941 |
| 1.02.01.10 | Other non-current assets | 71,975 | 62,190 |
| 1.02.01.10.04 | Judicial deposits | 33,368 | 29,215 |
| 1.02.01.09.05 | Taxes recoverable | 38,607 | 32,975 |
| 1.02.03 | Property and equipment | 1,446,532 | 1,276,276 |
| 1.02.04 | Intangible assets | 1,199,306 | 1,191,016 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIÁ DROGASIL S.A.

Consolidated financial information/balance sheet - liabilities and equity

(R\$ thousand)

| Code | Description | Current quarter 9/30/2018 | Prior year 12/31/2017 |
|---------------|---|------------------------------|--------------------------|
| 2 | Total liabilities and equity | 7,116,260 | 6,464,249 |
| 2.01 | Current liabilities | 2,728,540 | 2,493,779 |
| 2.01.01 | Social security and labor obligations | 288,636 | 202,799 |
| 2.01.01.01 | Social security obligations | 54,627 | 41,042 |
| 2.01.01.02 | Labor obligations | 234,009 | 161,757 |
| 2.01.02 | Trade payables | 1,862,896 | 1,815,687 |
| 2.01.02.01 | Domestic suppliers | 1,862,896 | 1,815,687 |
| 2.01.03 | Tax obligations | 82,483 | 130,432 |
| 2.01.03.01 | Federal tax obligations | 23,710 | 76,443 |
| 2.01.03.01.01 | Income tax and social contribution payable | 422 | 3,399 |
| 2.01.03.01.02 | Other federal tax obligations | 23,288 | 73,044 |
| 2.01.03.02 | State tax obligations | 55,037 | 51,941 |
| 2.01.03.03 | Municipal tax obligations | 3,736 | 2,048 |
| 2.01.04 | Borrowing | 237,205 | 196,248 |
| 2.01.04.01 | Borrowing | 106,551 | 126,741 |
| 2.01.04.01.01 | In local currency | 106,551 | 126,741 |
| 2.01.04.02 | Debentures | 130,654 | 69,507 |
| 2.01.04.02.01 | Debentures | 130,654 | 69,507 |
| 2.01.05 | Other obligations | 241,012 | 136,821 |
| 2.01.05.02 | Other | 241,012 | 136,821 |
| 2.01.05.02.01 | Dividends and interest on capital | 134,419 | 37,474 |
| 2.01.05.02.04 | Rentals | 72,693 | 65,768 |
| 2.01.05.02.06 | Other payables | 33,900 | 33,579 |
| 2.01.06 | Provision | 16,308 | 11,792 |
| 2.01.06.01 | Provision for tax, social security, labor and civil contingencies | 286 | 2,817 |
| 2.01.06.01.01 | Tax provision | 0 | 93 |
| 2.01.06.01.05 | Provision for legal claims | 286 | 2,724 |
| 2.01.06.02 | Other provisions | 16,022 | 8,975 |
| 2.01.06.02.06 | Provisions for sundry obligations | 16,022 | 8,975 |
| 2.02 | Non-current liabilities | 992,865 | 720,098 |
| 2.02.01 | Borrowing | 665,921 | 414,711 |
| 2.02.01.01 | Borrowing | 111,343 | 181,062 |
| 2.02.01.01.01 | In local currency | 111,343 | 181,062 |
| 2.02.01.02 | Debentures | 554,578 | 233,649 |
| 2.02.01.02.01 | Debentures | 554,578 | 233,649 |
| 2.02.02 | Other obligations | 63,600 | 68,503 |
| 2.02.02.02 | Other | 63,600 | 68,503 |
| 2.02.02.01.03 | Tax recovery program (REFIS) | 11,926 | 20,988 |
| 2.02.02.01.04 | Call option for additional shares | 51,674 | 47,515 |
| 2.02.03 | Deferred taxes | 256,905 | 228,715 |
| 2.02.03.01 | Deferred income tax and social contribution | 256,905 | 228,715 |
| 2.02.04 | Provision | 6,439 | 8,169 |
| 2.02.04.01 | Provision for tax, social security, labor and civil contingencies | 6,439 | 8,169 |
| 2.02.04.01.05 | Provision for legal claims | 6,439 | 8,169 |
| 2.03 | Consolidated equity | 3,394,855 | 3,250,372 |
| 2.03.01 | Paid-up share capital | 1,808,639 | 1,808,639 |
| 2.03.02 | Capital reserves | 113,518 | 151,156 |
| 2.03.04 | Revenue reserves | 1,228,149 | 1,280,751 |
| 2.03.04.01 | Legal reserve | 90,397 | 90,397 |
| 2.03.04.02 | Statutory reserve | 1,137,752 | 1,137,752 |
| 2.03.04.08 | Proposed additional dividends | 0 | 52,602 |
| 2.03.05 | Retained earnings (accumulated deficit) | 232,246 | 0 |
| 2.03.06 | Carrying value adjustments | -18,164 | -18,033 |
| 2.03.09 | Noncontrolling interests | 30,467 | 27,859 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RALA DROGASIL S.A.

Consolidated financial information/statement of income

(R\$ thousand)

| Code | Description | Current quarter 7/1/2018 to 9/30/2018 | Accumulated - prior year 1/1/2018 to 9/30/2018 | Same quarter - prior year 7/1/2017 to 9/30/2017 | Accumulated - prior year 1/1/2017 to 9/30/2017 |
|-------------|--|--|---|--|---|
| 3.01 | Net sales revenue | 3,756,814 | 10,804,380 | 3,416,840 | 9,711,209 |
| 3.01.01 | Gross sales revenue | 3,944,677 | 11,340,224 | 3,580,025 | 10,190,291 |
| 3.01.02 | Taxes on sales | -153,458 | -439,009 | -131,046 | -369,657 |
| 3.01.03 | Rebates | -34,405 | -96,835 | -32,139 | -109,425 |
| 3.02 | Cost of sales and/or services | -2,640,038 | -7,556,647 | -2,396,444 | -6,769,468 |
| 3.03 | Gross profit | 1,116,776 | 3,247,733 | 1,020,396 | 2,941,741 |
| 3.04 | Operating income/expenses | -930,546 | -2,675,216 | -810,693 | -2,348,126 |
| 3.04.01 | Selling expenses | -827,492 | -2,378,530 | -718,625 | -2,074,523 |
| 3.04.02 | General and administrative expenses | -99,552 | -286,944 | -92,068 | -271,443 |
| 3.04.02.01 | Administrative expenses | -99,552 | -286,944 | -92,068 | -271,443 |
| 3.04.05 | Other operating expenses | -3,502 | -9,742 | 0 | -2,160 |
| 3.04.05.01 | Extraordinary expenses | -3,502 | -9,742 | 0 | -2,160 |
| 3.05 | Profit before finance results and taxes | 186,230 | 572,517 | 209,703 | 593,615 |
| 3.06 | Finance results | -26,750 | -68,751 | -28,968 | -87,599 |
| 3.06.01 | Finance income | 19,468 | 54,271 | 28,231 | 85,257 |
| 3.06.02 | Finance costs | -46,218 | -123,022 | -57,199 | -172,856 |
| 3.07 | Profit before income tax and social contribution | 159,480 | 503,766 | 180,735 | 506,016 |
| 3.08 | Income tax and social contribution | -30,643 | -115,985 | -44,242 | -127,551 |
| 3.08.01 | Current | -29,237 | -87,727 | -31,391 | -103,018 |
| 3.08.02 | Deferred | -1,406 | -28,258 | -12,851 | -24,533 |
| 3.09 | Profit (loss) from continuing operations | 128,837 | 387,781 | 136,493 | 378,465 |
| 3.11 | Consolidated profit/loss for the period | 128,837 | 387,781 | 136,493 | 378,465 |
| 3.11.01 | Attributable to owners of the Company | 127,947 | 385,359 | 136,060 | 377,397 |
| 3.11.02 | Attributable to noncontrolling interests | 890 | 2,422 | 433 | 1,068 |
| 3.99 | Earnings per share - (Reais/share) | | | | |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RALA DROGASIL S.A.

Consolidated financial information/statement of comprehensive income

(R\$ thousand)

| Code | Description | Current quarter 7/1/2018 to 9/30/2018 | Accumulated - prior year 1/1/2018 to 9/30/2018 | Same quarter - prior year 7/1/2017 to 9/30/2017 | Accumulated - prior year 1/1/2017 to 9/30/2017 |
|-------------|--|--|---|--|---|
| 4.01 | Consolidated profit for the period | 128,837 | 387,781 | 136,493 | 378,465 |
| 4.03 | Consolidated comprehensive income for the period | 128,837 | 387,781 | 136,493 | 378,465 |
| 4.03.01 | Attributable to owners of the Company | 127,947 | 385,359 | 136,060 | 377,397 |
| 4.03.02 | Attributable to noncontrolling interests | 890 | 2,422 | 433 | 1,068 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Consolidated financial information/statement of cash flow - indirect method

(R\$ thousand)

| Code | Description | Accumulated - current year 1/1/2018 to 9/30/2018 | Accumulated - prior year 1/1/2017 to 9/30/2017 |
|------------|--|---|---|
| 6.01 | Net cash provided by operating activities | 352,708 | 411,360 |
| 6.01.01 | Cash from operations | 856,040 | 833,168 |
| 6.01.01.01 | Profit before income tax and social contribution | 503,766 | 506,016 |
| 6.01.01.02 | Depreciation and amortization | 301,824 | 245,792 |
| 6.01.01.03 | Share-based compensation plan | 9,329 | 9,509 |
| 6.01.01.04 | Interest on call option for additional shares | 4,159 | 7,287 |
| 6.01.01.05 | Result on disposal of property and equipment and intangible assets | 7,272 | 4,656 |
| 6.01.01.06 | (Reversal) provision for legal claims | -3,677 | 7,866 |
| 6.01.01.07 | (Reversal) provision for inventory losses | -1,036 | 1,952 |
| 6.01.01.08 | (Reversal) provision for impairment of trade receivables | -4,104 | 1,726 |
| 6.01.01.09 | (Reversal) provision for store closures | -1,228 | -2,340 |
| 6.01.01.10 | Interest expenses | 42,618 | 50,581 |
| 6.01.01.11 | Amortization of transaction cost of debentures | -2,883 | 123 |
| 6.01.02 | Changes in assets and liabilities | -380,180 | -312,291 |
| 6.01.02.01 | Trade receivables and other receivables | -116,562 | -129,257 |
| 6.01.02.02 | Inventory | -288,272 | -191,178 |
| 6.01.02.03 | Other current assets | -7,938 | 19,003 |
| 6.01.02.04 | Long-term receivables | -46,764 | -15,223 |
| 6.01.02.05 | Trade payables | 42,747 | -44,775 |
| 6.01.02.06 | Salaries and social charges | 85,837 | 52,245 |
| 6.01.02.07 | Taxes and contributions | -53,832 | -7,953 |
| 6.01.02.08 | Other liabilities | -2,321 | -405 |
| 6.01.02.09 | Rentals payable | 6,925 | 5,252 |
| 6.01.03 | Other | -123,152 | -109,517 |
| 6.01.03.01 | Interest paid | -19,708 | -17,694 |
| 6.01.03.02 | Income tax and social contribution paid | -103,444 | -91,823 |
| 6.02 | Net cash used in investing activities | -482,063 | -479,726 |
| 6.02.01 | Purchases of property and equipment and intangible assets | -482,073 | -480,329 |
| 6.02.02 | Proceeds from sale of property and equipment | 10 | 603 |
| 6.03 | Net cash used in financing activities | 138,037 | 186,297 |
| 6.03.01 | Borrowing | 406,960 | 393,960 |
| 6.03.02 | Repayments of borrowing | -134,820 | -122,448 |
| 6.03.03 | Repurchase of shares | -46,925 | 0 |
| 6.03.04 | Interest on capital and dividends paid | -87,178 | -85,215 |
| 6.05 | Increase (decrease) in cash and cash equivalents | 8,682 | 117,931 |
| 6.05.01 | Cash and cash equivalents at the beginning of the period | 264,873 | 276,632 |
| 6.05.02 | Cash and cash equivalents at the end of the period | 273,555 | 394,563 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIÁ DROGASIL S.A.

Consolidated financial information/statement of changes in equity - 1/1/2018 to 9/30/2018

(R\$ thousand)

| Code | Description | Paid-up share capital | Capital reserves, options granted and treasury shares | Revenue reserves | Retained earnings/ accumulated deficit | Other comprehensive income | Equity | Non- controlling interests | Consolidated equity |
|---------|---|-----------------------------|--|---------------------|---|----------------------------------|-----------|----------------------------------|------------------------|
| 5.01 | Opening balance | 1,808,639 | 151,156 | 1,280,751 | 0 | -18,033 | 3,222,513 | 27,859 | 3,250,372 |
| 5.03 | Adjusted opening balance | 1,808,639 | 151,156 | 1,280,751 | 0 | -18,033 | 3,222,513 | 27,859 | 3,250,372 |
| 5.04 | Equity transactions with owners | 0 | -37,638 | -52,602 | -153,244 | 0 | -243,484 | 186 | -243,298 |
| 5.04.07 | Interest on capital | 0 | 0 | 0 | -153,500 | 0 | -153,500 | 0 | -153,500 |
| 5.04.08 | Interest on capital of 2017 approved at the AGM of March 28, 2018 | 0 | 0 | -52,602 | 0 | 0 | -52,602 | 0 | -52,602 |
| 5.04.09 | Interest on capital expired | 0 | 0 | 0 | 256 | 0 | 256 | 0 | 256 |
| 5.04.10 | Restricted share plan - Vesting period | 0 | 9,287 | 0 | 0 | 0 | 9,287 | 0 | 9,287 |
| 5.04.11 | Restricted share plan - Delivery | 0 | -7,382 | 0 | 0 | 0 | -7,382 | 0 | -7,382 |
| 5.04.12 | Goodwill on sale of shares | 0 | 3,115 | 0 | 0 | 0 | 3,115 | 0 | 3,115 |
| 5.04.13 | Treasury shares – Delivery | 0 | 4,267 | 0 | 0 | 0 | 4,267 | 0 | 4,267 |
| 5.04.14 | Repurchase of shares | 0 | -46,925 | 0 | 0 | 0 | -46,925 | 0 | -46,925 |
| 5.04.15 | Noncontrolling interest in investment acquired | 0 | 0 | 0 | 0 | 0 | 0 | 186 | 186 |
| 5.05 | Total comprehensive income | 0 | 0 | 0 | 385,359 | 0 | 385,359 | 2,422 | 387,781 |
| 5.05.01 | Profit for the period | 0 | 0 | 0 | 385,359 | 0 | 385,359 | 2,422 | 387,781 |
| 5.06 | Internal changes in equity | 0 | 0 | 0 | 131 | -131 | 0 | 0 | 0 |
| 5.06.02 | Realization of revaluation reserve | 0 | 0 | 0 | 199 | -199 | 0 | 0 | 0 |
| 5.06.03 | Taxes on realization of revaluation reserve | 0 | 0 | 0 | -68 | 68 | 0 | 0 | 0 |
| 5.07 | Closing balance | 1,808,639 | 113,518 | 1,228,149 | 232,246 | -18,164 | 3,364,388 | 30,467 | 3,394,855 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIÁ DROGASIL S.A.

Consolidated financial information/statement of changes in equity - 1/1/2017 to 9/30/2017

(R\$ thousand)

| Code | Description | Paid-up share capital | Capital reserves, options granted and treasury shares | Revenue reserves | Retained earnings/ accumulated deficit | Other comprehensive income | Equity | Non- controlling interests | Consolidated equity |
|---------|---|-----------------------------|--|---------------------|---|----------------------------------|-----------|----------------------------------|------------------------|
| 5.01 | Opening balance | 1,808,639 | 138,553 | 980,442 | 0 | -17,847 | 2,909,787 | 26,168 | 2,935,955 |
| 5.03 | Adjusted opening balance | 1,808,639 | 138,553 | 980,442 | 0 | -17,847 | 2,909,787 | 26,168 | 2,935,955 |
| 5.04 | Equity transactions with owners | 0 | 9,486 | -61,324 | -150,918 | 0 | -202,756 | 387 | -202,369 |
| 5.04.07 | Interest on capital | 0 | 0 | 0 | -151,000 | 0 | -151,000 | 0 | -151,000 |
| 5.04.08 | Interest on capital of 2016 approved at the AGM of March 29, 2017 | 0 | 0 | -61,324 | 0 | 0 | -61,324 | 0 | -61,324 |
| 5.04.09 | Interest on capital expired | 0 | 0 | 0 | 82 | 0 | 82 | 0 | 82 |
| 5.04.10 | Restricted share plan - Vesting period | 0 | 9,486 | 0 | 0 | 0 | 9,486 | 0 | 9,486 |
| 5.04.11 | Restricted shares – Delivery | 0 | -4,863 | 0 | 0 | 0 | -4,863 | 0 | -4,863 |
| 5.04.12 | Goodwill on sale of shares | 0 | 1,382 | 0 | 0 | 0 | 1,382 | 0 | 1,382 |
| 5.04.13 | Treasury shares – Delivery | 0 | 3,481 | 0 | 0 | 0 | 3,481 | 0 | 3,481 |
| 5.04.14 | Noncontrolling interest in investment acquired | 0 | 0 | 0 | 0 | 0 | 0 | 387 | 387 |
| 5.05 | Total comprehensive income | 0 | 0 | 0 | 377,397 | 0 | 377,397 | 1,068 | 378,465 |
| 5.05.01 | Profit for the period | 0 | 0 | 0 | 377,397 | 0 | 377,397 | 1,068 | 378,465 |
| 5.06 | Internal changes in equity | 0 | 0 | 0 | 140 | -140 | 0 | 0 | 0 |
| 5.06.02 | Realization of revaluation reserve | 0 | 0 | 0 | 212 | -212 | 0 | 0 | 0 |
| 5.06.03 | Taxes on realization of revaluation reserve | 0 | 0 | 0 | -72 | 72 | 0 | 0 | 0 |
| 5.07 | Closing balance | 1,808,639 | 148,039 | 919,118 | 226,619 | -17,987 | 3,084,428 | 27,623 | 3,112,051 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIÁ DROGASIL S.A.

Consolidated financial information/statement of value added

(R\$ thousand)

| Code | Description | Accumulated - current year 1/1/2018 to 9/30/2018 | Accumulated - prior year 1/1/2017 to 9/30/2017 |
|-------------|---|---|---|
| 7.01 | Revenue | 11,248,263 | 10,079,633 |
| 7.01.01 | Sales of products and services | 11,243,527 | 10,080,898 |
| 7.01.02 | Other income | 632 | 461 |
| 7.01.04 | Provision for/reversal of impairment of trade receivables | 4,104 | -1,726 |
| 7.02 | Inputs acquired from third parties | -7,553,563 | -6,701,572 |
| 7.02.01 | Cost of sales and services | -6,927,792 | -6,165,493 |
| 7.02.02 | Materials, energy, outsourced services and other | -619,752 | -533,322 |
| 7.02.03 | Impairment/recovery of assets | -6,019 | -2,757 |
| 7.03 | Gross value added | 3,694,700 | 3,378,061 |
| 7.04 | Retentions | -301,824 | -245,792 |
| 7.04.01 | Depreciation, amortization and depletion | -301,824 | -245,792 |
| 7.05 | Net value added generated by the entity | 3,392,876 | 3,132,269 |
| 7.06 | Value added received through transfer | 57,864 | 85,257 |
| 7.06.02 | Finance income | 54,866 | 85,257 |
| 7.06.03 | Other | 2,998 | 0 |
| 7.07 | Total value added to distribute | 3,450,740 | 3,217,526 |
| 7.08 | Distribution of value added | 3,450,740 | 3,217,526 |
| 7.08.01 | Personnel | 1,122,673 | 1,002,128 |
| 7.08.01.01 | Direct remuneration | 876,291 | 799,744 |
| 7.08.01.02 | Benefits | 169,218 | 144,836 |
| 7.08.01.03 | Unemployment compensation fund | 77,164 | 57,548 |
| 7.08.02 | Taxes and contributions | 1,383,261 | 1,313,624 |
| 7.08.02.01 | Federal | 395,967 | 375,063 |
| 7.08.02.02 | State | 970,243 | 923,393 |
| 7.08.02.03 | Municipal | 17,051 | 15,168 |
| 7.08.03 | Providers of capital | 557,025 | 523,310 |
| 7.08.03.01 | Interest | 121,362 | 171,088 |
| 7.08.03.02 | Rentals | 435,663 | 352,222 |
| 7.08.04 | Stockholders and the Company | 387,781 | 378,464 |
| 7.08.04.01 | Interest on capital | 153,500 | 151,000 |
| 7.08.04.03 | Profits reinvested/loss for the period | 231,859 | 226,397 |
| 7.08.04.04 | Noncontrolling interests in retained earnings | 2,422 | 1,067 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIÁ DROGASIL S.A.

Comments on company performance

São Paulo, October 30, 2018. **RD – People, Health and Well-being** (Raia Drogasil S.A. – B3: RADL3) announces today its results for the 3rd quarter of 2018 (3Q18). The Company's parent company and consolidated quarterly financial statements for the periods ended in September 30, 2018 and 2017 have been prepared in accordance with technical pronouncement CPC 21 (R1) – “Interim Financial Reporting”, the requirements in Official Letter/CVM/SNC/SEP 003/2011 of April 28, 2011, and the International Financial Reporting Standards (IFRS) – IAS 34 and discloses all material information specific to the individual and consolidated quarterly information, which is consistent with the information used by management in managing the activities. Such information was prepared in Reais and all growth rates relate to the same period of 2017.

QUARTERLY HIGHLIGHTS:

- › **DRUGSTORES:** 1,768 stores in operation (64 openings and 4 closures)
- › **GROSS REVENUES:** R\$ 3.9 billion, 10.2% growth (0.8% retail same-store sales growth)
- › **GROSS MARGIN:** 28.3% of gross revenues, a 0.2 percentage point decrease
- › **EBITDA:** R\$ 295.3 million, a margin of 7.5%, a 0.8 percentage point pressure
- › **NET INCOME:** R\$ 131.1 million, 3.3% of net margin
- › **CASH FLOW:** R\$ 0.9 million free cash flow, R\$ 1.4 million of cash generation


| Summary | 3Q17 | 4Q17 | 1Q18 | 2Q18 | 3Q18 |
|-----------------------------|-----------|-----------|-----------|-----------|-----------|
| <i>(R\$ thousand)</i> | | | | | |
| # of Stores - Retail + 4Bio | 1,554 | 1,610 | 1,651 | 1,708 | 1,768 |
| Store Openings | 54 | 60 | 44 | 62 | 64 |
| Store Closures | (6) | (4) | (3) | (5) | (4) |
| # of Stores (average) | 1,533 | 1,588 | 1,629 | 1,680 | 1,744 |
| Headcount (EoP) | 31,163 | 32,265 | 32,633 | 33,880 | 34,708 |
| Pharmacist Count (EoP) | 5,977 | 6,044 | 6,323 | 6,582 | 6,806 |
| # of Tickets (000) | 52,798 | 53,957 | 52,291 | 55,148 | 56,560 |
| Gross Revenue | 3,580,024 | 3,662,178 | 3,603,969 | 3,791,578 | 3,944,677 |
| Gross Profit | 1,020,396 | 1,046,258 | 1,026,758 | 1,104,199 | 1,116,776 |
| % of Gross Revenues | 28.5% | 28.6% | 28.5% | 29.1% | 28.3% |
| Adjusted EBITDA | 296,463 | 288,719 | 272,185 | 316,648 | 295,250 |
| % of Gross Revenues | 8.3% | 7.9% | 7.6% | 8.4% | 7.5% |
| Adjusted Net Income | 136,493 | 132,623 | 121,288 | 141,775 | 131,148 |
| % of Gross Revenues | 3.8% | 3.6% | 3.4% | 3.7% | 3.3% |
| Net Income | 136,493 | 134,188 | 121,288 | 137,656 | 128,837 |
| % of Gross Revenues | 3.8% | 3.7% | 3.4% | 3.6% | 3.3% |
| Free Cash Flow | 102,135 | 68,432 | (102,012) | (67,705) | 681 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIÁ DROGASIL S.A.

Comments on company performance

STORE DEVELOPMENT



We opened 64 new stores and closed 4 in the 3Q18, ending the quarter with 1,768 stores, including three 4Bio units. We reiterate our guidance of 240 gross openings per year for both 2018 and 2019. At the end of the period, 36.4% of our stores were still in the process of maturation and had not yet reached their full potential both in terms of revenue and of profitability. It is important to mention that the performance of the stores opened this year remains very robust, in line with our historical standards.

We recorded four store closures in the quarter, all under the Farmasil brand. This is a consequence of the enhancement of our popular store format, which will leverage the existing operating model of Farmasil at larger store areas (120 m² to 140 m²) and by using the Raia and Drogasil brands, resulting in the closure of the stores in which the sales areas cannot be increased.

Our national market share reached 12.0% in the 3Q18, a 0.3 percentage point increase when compared to the same period of the previous year. IMS recorded a market growth of only 8.2% in the quarter, supported by a 7.2% growth in units. This reflects the erosion of average prices arising from the down trade to cheaper Generics.


Still, we increased our market share in four of the six regions where we operate under a context of increased competition due to accelerated store addition from the other chains. The Northeast remained as our main highlight, where we recorded a market share of 6.1%, a 0.9 percentage point increase driven by our organic expansion and store maturation. We also recorded market share gains in the South and Southeast regions of 0.3 percentage point, reaching a total of 6.6% and 8.0%, respectively. On the other hand, we have lost 0.5 percentage point of market share in São Paulo, reaching a total of 22.1% and lost 0.4 percentage point in the Midwest, reaching a share of 13.2%.

Our market share in São Paulo was impacted by the deceleration of our LTM expansion from 93 stores in the 3Q17 to 76 in the 3Q18, reflecting an increased decentralization in our growth. It is also a consequence of our investments in prices and mix, especially in generics, which resulted in a lower average ticket but allowed us to maintain a constant market share in São Paulo in terms of units sold when compared to the 3Q17.

(A free translation of the original in Portuguese)


Quarterly information (ITR) - 9/30/2018 - RAIÁ DROGASIL S.A.

Comments on company performance



GROSS REVENUES

We ended the 3Q18 with consolidated gross revenues of R\$ 3,944.7 million, a 10.2% increase over the same period of the previous year. Our drugstore revenues increased by 8.9%, while 4Bio grew 40.4% in the period.




(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIÁ DROGASIL S.A.


Comments on company performance

OTC was the highlight of the quarter by growing 12.9% and gaining 0.6 percentage point. HPC grew 10.4%, gaining 0.3 percentage point. On the other hand, Branded Rx grew 7.2% in the quarter, losing 0.7 percentage point. The outperformance by OTC at the expense of Branded was helped by drug switches, a migration of 0.4 percentage point. Generic revenues grew 6.0%, supported by a significant growth in Generics units sold, reflecting our successful investment in pricing while preserving the total retail gross margin.



Our same store sales increased by 0.8%, while our mature stores declined by 3.2%, with a negative calendar effect of 0.3%. Sequential deceleration was driven by the very strong comp base of the 3Q17.

GROSS MARGIN



(A free translation of the original in Portuguese)


Quarterly information (ITR) - 9/30/2018 - RAIÁ DROGASIL S.A.

Comments on company performance

Our gross margin reached 28.3%, a 0.2 percentage point pressure versus the 3Q17. We recorded a 0.1 percentage point retail margin increase and a 0.3 percentage point pressure from 4Bio, due to its negative mix effect.

SELLING EXPENSES

In the 3Q18, selling expenses totaled R\$ 735.4 million, equivalent to 18.6% of gross revenues, a 0.7 percentage point pressure compared to the same quarter of the previous year.



We recorded personnel expenses pressure of 0.3 percentage point, as well as 0.2 percentage point pressure from rentals, 0.1 percentage point from logistics, and another 0.1 percentage point from electricity. Also, we recorded another 0.2 percentage point pressure from new stores opened in the quarter as well as from those in the opening process, mostly due to the acceleration in the expansion pace and to accumulation of pre-operational expenses related to the new stores in the Pará state, which carry a higher average rental expense. These pressures were partially offset by a 0.2 percentage point dilution from 4Bio, which has lower selling expenses and recorded an expense dilution in the quarter.

These pressures were driven by the tough comps of the 3Q17, when the expense level was below the 4Q17 by 0.4 percentage point, as well as by the loss of operating leverage due to a mature-stores sales performance below inflation, which accounted for the balance.


GENERAL & ADMINISTRATIVE EXPENSES

G&A expenses amounted to R\$ 86.1 million in the 3Q18, equivalent to 2.2% of gross revenues and a 0.1 percentage point dilution over the 3Q17. This expense dilution reflects a lower variable compensation allowance in the quarter compared to the previous year and also to other gains stemming from economies of scale.

(A free translation of the original in Portuguese)


Quarterly information (ITR) - 9/30/2018 - RAIÁ DROGASIL S.A.

Comments on company performance



EBITDA

Our adjusted EBITDA reached R\$ 295.3 million in the quarter, an EBITDA margin of 7.5% and a 0.8 percentage point pressure over the same period of last year.



New stores opened in the year, as well as those in the opening process, reduced the EBITDA by R\$ 11.6 million. Therefore, considering only the 1,598 stores in operation since the end of 2017 and the full absorption of logistics, general and administrative expenses by such stores, our EBITDA would have totaled R\$ 306.8 million, equivalent to a margin of 8.1% and a 0.7 percentage point pressure.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Comments on company performance


RD Pharmacies reached an adjusted EBITDA of R\$ 291.0 and a margin of 7.8% in the 3Q18, a 0.8 percentage point pressure over the same period of last year. Gross margin increased by 0.1 percentage point, while expenses pressured by 0.9 percentage point. It is important to mention that a significant part of this pressure was due to the very strong comp base of the 3Q17, when the selling expense level was below the 4Q17 by 0.4 percentage point. Therefore, the loss of operating leverage accounted for a margin pressure of 0.5 percentage point in the retail operation.

Finally, 4Bio reached an EBITDA of R\$ 4.2 million and a margin of 2.1%, a 0.3 percentage point margin expansion.

| EBITDA Reconciliation | 3Q17 | 3Q18 |
|--|--------------|--------------|
| <i>(R\$ million)</i> | | |
| Net Income | 136.5 | 128.8 |
| (+) Income Tax | 44.2 | 30.6 |
| (+) Financial Result | 29.0 | 26.7 |
| EBIT | 209.7 | 186.2 |
| (+) Depreciation and Amortization | 86.8 | 105.5 |
| EBITDA | 296.5 | 291.7 |
| (+) Expenses related to the Strategic Planning | - | 2.2 |
| (+) Asset Write-off - Farmasil | - | 1.3 |
| Adjusted EBITDA | 296.5 | 295.3 |

During the 3Q18, we recorded R\$ 3.5 million in non-recurring expenses, which included R\$ 2.2 million in consulting expenses related to the development of our Strategic Planning for the next five years and R\$ 1.3 million in asset write-off related to the closure of 4 Farmasil stores which cannot be upgraded to our enhanced popular format.

DEPRECIATION, NET FINANCIAL EXPENSES AND INCOME TAXES



Depreciation expenses amounted to R\$ 105.5 million in the 3Q18, equivalent to 2.7% of gross revenues, a 0.3 percentage point increase reflecting the acceleration of our expansion program and a lower dilution due to a weaker sales performance.

Financial expenses totaled 0.7% of revenues, a 0.1 percentage point decrease. Of the R\$ 26.7 million, R\$ 11.9 million refers to the NPV adjustment while other R\$ 1.4 million refers to interest on the option to acquire the remaining 45% of 4Bio. Excluding the NPV adjustments and expenses related to the option to acquire 4Bio, interest accrued on net debt amounted to R\$ 13.4 million, equivalent

(A free translation of the original in Portuguese)


Quarterly information (ITR) - 9/30/2018 - RAIÁ DROGASIL S.A.

Comments on company performance

to 0.3 percentage point of gross revenues. We booked R\$ 31.8 million in income taxes, equivalent to 0.8% of gross revenues.


NET INCOME

Adjusted Net income totaled R\$ 131.1 million in the quarter, a 3.9% decrease over the same period of the previous year. We achieved a net margin of 3.3%, a 0.5 percentage point pressure over the 3Q17.



CASH CYCLE

Our cash cycle increased by 4.8 days. Inventories increased by 7.9 days, partially offset by an accounts payable increase of 5.0 days. Lastly, receivables increased by 1.9 day, reflecting an unfavorable calendar and a higher penetration of credit and debit cards.



* Adjusted to discounted receivables.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIÁ DROGASIL S.A.

Comments on company performance

CASH FLOW

In the 3Q18, we recorded a free cash flow of R\$ 0.7 million, and a negative total cash flow of R\$ 1.4 million.

Resources from operations amounted to R\$ 224.6 million, equivalent to 5.7% of gross revenues, while we recorded a working capital investment of R\$ 32.2 million (reincorporating the discounted receivables), amounting to a total operating cash flow of R\$ 192.4 million.

Of the R\$ 191.7 million invested in the quarter, R\$ 127.4 million corresponded to new store openings, R\$ 40.1 million to the renovation or expansion of existing stores and R\$ 24.2 million to investments in infrastructure.

Net financial expenses totaled R\$ 14.8 million in the quarter, excluding NPV adjustments. These were more than fully offset by the R\$ 22.7 million tax shield related to the net financial expenses and to the interest on equity accrued in the period, which shall be paid in the following quarters.

We accrued R\$ 52.0 million in interest on equity in the 3Q18, reflecting a payout of 40.4%, through the full usage of the legal interest on equity limit.

| Cash Flow | 3Q18 | 3Q17 | YTD '18 | YTD '17 |
|---|----------------|----------------|----------------|----------------|
| <i>(R\$ million)</i> | | | | |
| Adjusted EBIT | 189.7 | 209.7 | 582.3 | 595.8 |
| NPV Adjustment | (12.7) | (17.0) | (33.8) | (49.3) |
| Non-Recurring Expenses | (3.5) | - | (9.7) | (2.2) |
| Income Tax (34%) | (59.0) | (65.5) | (183.2) | (185.1) |
| Depreciation | 105.5 | 86.8 | 301.8 | 245.8 |
| Others | 4.5 | 3.2 | 6.6 | 23.4 |
| Resources from Operations | 224.6 | 217.1 | 664.0 | 628.4 |
| Cash Cycle* | (39.1) | 30.7 | (362.3) | (365.2) |
| Other Assets (Liabilities)** | 6.9 | 45.7 | 11.4 | 98.4 |
| Operating Cash Flow | 192.4 | 293.6 | 313.0 | 361.6 |
| Investments | (191.7) | (191.4) | (482.1) | (479.7) |
| Free Cash Flow | 0.7 | 102.1 | (169.0) | (118.1) |
| Interest on Equity | (0.0) | (0.0) | (87.2) | (85.2) |
| Income Tax Paid over Interest on Equity | (7.1) | (6.9) | (14.2) | (14.0) |
| Net Financial Expenses*** | (14.8) | (14.7) | (34.4) | (42.3) |
| Share Buyback | - | - | (46.9) | - |
| Income Tax (Tax benefit over financial expenses and interest on equity) | 22.7 | 22.3 | 63.9 | 65.7 |
| Total Cash Flow | 1.4 | 102.8 | (287.9) | (193.9) |

*Includes adjustments to discounted receivables.

**Includes tax shield from goodwill amortization and NPV adjustments.

***Excludes NPV adjustments.

INDEBTEDNESS

At the end of the quarter, we recorded an adjusted net debt position of R\$ 681.5 million, versus R\$ 376.4 million recorded in the same period of 2017. The adjusted Net Debt to EBITDA totaled 0.6x, 0.3x higher than the 3Q17 reflecting the acceleration in our expansion plan.

This net debt includes R\$ 51.7 million in liability related to the exercise of the put option granted and/or call option obtained for the acquisition of the remaining 45% minority stake of 4Bio. This liability reflects the estimated valuation of 4Bio as of December 2017, assuming the pre-agreed multiple, the average forecasted annual EBITDA for 2018, 2019 and 2020 and the forecasted average net debt for 2020 as stipulated in the acquisition contracts. This estimate is revisited annually to reflect changes in the economic outlook of 4Bio. Further, 4Bio ended the quarter with R\$ 0.2 million in discounted receivables.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Comments on company performance


| Net Debt | 3Q17 | 4Q17 | 1Q18 | 2Q18 | 3Q18 |
|---|--------------|--------------|--------------|--------------|--------------|
| <i>(R\$ million)</i> | | | | | |
| Short-term Debt | 231.8 | 196.2 | 186.2 | 227.2 | 237.2 |
| Long-term Debt | 486.7 | 414.7 | 387.3 | 684.4 | 665.9 |
| Total Gross Debt | 718.5 | 611.0 | 573.5 | 911.6 | 903.1 |
| (-) Cash and Equivalents | 394.6 | 264.9 | 102.7 | 281.3 | 273.6 |
| Net Debt | 323.9 | 346.1 | 470.8 | 630.4 | 629.6 |
| Discounted Receivables | - | - | 9.1 | 2.3 | 0.2 |
| Put/Call option to acquire 4Bio (estimated) | 52.5 | 47.5 | 48.9 | 50.2 | 51.7 |
| Adjusted Net Debt | 376.4 | 393.6 | 528.8 | 682.9 | 681.5 |
| Adjusted Net Debt / EBITDA | 0.3x | 0.3x | 0.5x | 0.6x | 0.6x |

Our gross debt totaled R\$ 903.1 million, of which 23.4% correspond to BNDES (Brazilian Economic and Social Development Bank) lines, 75.9% correspond to the debentures issued on April 2017 and 2018 and 0.7% are related to other financing lines. Of our total debt, 73.7% is long-term, while 26.3% relates to its short-term parcels. We ended the quarter with a total cash position (cash and marketable securities) of R\$ 273.6 million.

TOTAL SHAREHOLDER RETURN

Our share price increased by 9.1% in the 3Q18 versus a 9.0% increase of the Ibovespa. Since the IPO of Drogasil, we achieved a cumulative share appreciation of 1,390.3% versus a return of only 45.9% for the Ibovespa. Considering the IPO of Raia in December of 2010, the cumulative return amounted to 605.6% versus an increase of only 16.7% of the Ibovespa. Considering the payment of interest on equity, this resulted in an average annual total return to shareholders of 27.6%.

We recorded an average daily trading volume of R\$ 83.8 million in the quarter.



(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Comments on company performance

| Adjusted Income Statement <i>(R\$ thousand)</i> | 3Q17 | 3Q18 |
|---|------------------|------------------|
| Gross Revenue | 3,580,024 | 3,944,677 |
| Taxes, Discounts and Returns | (163,184) | (187,863) |
| Net Revenue | 3,416,840 | 3,756,814 |
| Cost of Goods Sold | (2,396,444) | (2,640,038) |
| Gross Profit | 1,020,396 | 1,116,776 |
| Operational (Expenses) Revenue | | |
| Sales | (642,400) | (735,403) |
| General and Administrative | (81,533) | (86,123) |
| Operational Expenses | (723,933) | (821,525) |
| EBITDA | 296,463 | 295,250 |
| Depreciation and Amortization | (86,760) | (105,518) |
| Operational Earnings before Financial Results | 209,703 | 189,732 |
| Financial Expenses | (57,199) | (46,218) |
| Financial Revenue | 28,231 | 19,468 |
| Financial Expenses/Revenue | (28,968) | (26,750) |
| Earnings before Income Tax and Social Charges | 180,735 | 162,982 |
| Income Tax and Social Charges | (44,242) | (31,834) |
| Net Income | 136,493 | 131,148 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Comments on company performance

| Consolidated Income Statement <i>(R\$ thousand)</i> | 3Q17 | 3Q18 |
|---|------------------|------------------|
| Gross Revenue | 3,580,024 | 3,944,677 |
| Taxes, Discounts and Returns | (163,184) | (187,863) |
| Net Revenue | 3,416,840 | 3,756,814 |
| Cost of Goods Sold | (2,396,444) | (2,640,038) |
| Gross Profit | 1,020,396 | 1,116,776 |
| Operational (Expenses) Revenue | | |
| Sales | (642,400) | (735,403) |
| General and Administrative | (81,533) | (86,123) |
| Other Operational Expenses, Net | 0 | (3,502) |
| Operational Expenses | (723,933) | (825,027) |
| EBITDA | 296,463 | 291,748 |
| Depreciation and Amortization | (86,760) | (105,518) |
| Operational Earnings before Financial Results | 209,703 | 186,230 |
| Financial Expenses | (57,199) | (46,218) |
| Financial Revenue | 28,231 | 19,468 |
| Financial Expenses/Revenue | (28,968) | (26,750) |
| Earnings before Income Tax and Social Charges | 180,735 | 159,480 |
| Income Tax and Social Charges | (44,242) | (30,643) |
| Net Income | 136,493 | 128,837 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Comments on company performance

| Assets | 3Q17 | 3Q18 |
|-------------------------------|------------------|------------------|
| <i>(R\$ thousand)</i> | | |
| Current Assets | | |
| Cash and Cash Equivalents | 394,563 | 273,555 |
| Accounts Receivable | 869,801 | 1,041,121 |
| Inventories | 2,338,694 | 2,806,902 |
| Taxes Receivable | 83,703 | 75,027 |
| Other Accounts Receivable | 135,386 | 169,396 |
| Anticipated Expenses | 21,725 | 29,574 |
| | <u>3,843,871</u> | <u>4,395,575</u> |
| Non-Current Assets | | |
| Deposit in Court | 27,947 | 33,369 |
| Taxes Receivable | 33,162 | 38,880 |
| Other Credits | 4,973 | 2,599 |
| Property, Plant and Equipment | 1,212,884 | 1,446,532 |
| Intangible | 1,186,998 | 1,199,306 |
| | <u>2,465,964</u> | <u>2,720,685</u> |
| ASSETS | <u>6,309,835</u> | <u>7,116,260</u> |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Comments on company performance

| Liabilities and Shareholder's Equity <i>(R\$ thousand)</i> | 3Q17 | 3Q18 |
|--|------------------|------------------|
| Current Liabilities | | |
| Suppliers | 1,558,783 | 1,862,896 |
| Loans and Financing | 231,775 | 237,205 |
| Salaries and Social Charges Payable | 251,623 | 288,636 |
| Taxes Payable | 121,243 | 82,483 |
| Dividend and Interest on Equity | 131,373 | 134,419 |
| Provision for Lawsuits | 4,042 | 286 |
| Other Accounts Payable | 117,837 | 122,614 |
| | <u>2,416,676</u> | <u>2,728,540</u> |
| Non-Current Liabilities | | |
| Loans and Financing | 486,715 | 665,921 |
| Provision for Lawsuits | 7,395 | 6,439 |
| Income Tax and Social Charges deferred | 217,650 | 256,905 |
| Other Accounts Payable | 69,349 | 63,599 |
| | <u>781,109</u> | <u>992,865</u> |
| Shareholder's Equity | | |
| Common Stock | 1,808,639 | 1,808,639 |
| Capital Reserves | 148,039 | 113,518 |
| Revaluation Reserve | 12,244 | 12,066 |
| Income Reserves | 919,117 | 1,228,149 |
| Accrued Income | 226,619 | 232,247 |
| Equity Adjustments | (30,230) | (30,230) |
| Non Controller Interest | 27,623 | 30,467 |
| | <u>3,112,050</u> | <u>3,394,855</u> |
| LIABILITIES AND SHAREHOLDERS' EQUITY | <u>6,309,835</u> | <u>7,116,260</u> |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIÁ DROGASIL S.A.

Comments on company performance

| Cash Flow | 3Q17 | 3Q18 |
|---|------------------|------------------|
| <i>(R\$ thousand)</i> | | |
| Earnings before Income Tax and Social Charges | 180,735 | 159,480 |
| Adjustments | | |
| Depreciation and Amortization | 86,760 | 105,518 |
| Compensation plan with restricted shares, net | 3,317 | 3,186 |
| Interest over additional stock option | 2,550 | 1,425 |
| P,P&E and Intangible Assets residual value | 1,970 | 2,751 |
| Provisioned Lawsuits | (1,157) | (572) |
| Provisioned Inventory Loss | (92) | (1,105) |
| Provision for Doubtful Accounts | 924 | 268 |
| Provisioned Store Closures | (1,787) | 0 |
| Interest Expenses | 18,515 | 16,107 |
| Debt Issuance Costs Amortization | 63 | 513 |
| | 291,798 | 287,571 |
| Assets and Liabilities variation | | |
| Clients and Other Accounts Receivable | (48,713) | (68,462) |
| Inventories | (84,042) | (164,998) |
| Other Short Term Assets | 8,157 | (2,545) |
| Long Term Assets | (4,094) | (43,393) |
| Suppliers | 163,485 | 192,339 |
| Salaries and Social Charges | 26,735 | 34,413 |
| Taxes Payable | 4,927 | 4,011 |
| Other Liabilities | (6,628) | 6,027 |
| Rent Payable | 3,027 | 5,497 |
| Cash from Operations | 354,652 | 250,460 |
| Interest Paid | (5,537) | (2,874) |
| Income Tax and Social Charges Paid | (39,248) | (41,308) |
| Net Cash from (invested) Operational Activities | 309,867 | 206,278 |
| Investment Activities Cash Flow | | |
| P,P&E and Intangible Acquisitions | (191,469) | (191,737) |
| P,P&E Sale Payments | 37 | 3 |
| Net Cash from Investment Activities | (191,432) | (191,734) |
| Financing Activities Cash Flow | | |
| Funding | 0 | 6,373 |
| Payments | (48,218) | (28,613) |
| Interest on Equity and Dividends Paid | (17) | (3) |
| Net Cash from Funding Activities | (48,235) | (22,243) |
| Cash and Cash Equivalents net increase | 70,200 | (7,699) |
| Cash and Cash Equivalents in the beginning of the period | 324,363 | 281,254 |
| Cash and Cash Equivalents in the end of the period | 394,563 | 273,556 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

1. Operations

Raia Drogasil S.A. (the "Company") is a publicly-held company listed on the Novo Mercado ("New Market") listing segment of B3 S.A. - Brasil, Bolsa, Balcão, - with its headquarters in the capital of the state of São Paulo.

Raia Drogasil S.A. and its subsidiary 4Bio S.A. (together "Consolidated" or "Group") are mainly engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics and specialty medicines.

The Group performs its sales through 1,768 stores (1,610 stores - Dec-2017), distributed in 22 Brazilian states, as follows:

| | Consolidated |
|---------------------|---------------------|
| | Sep-2018 |
| São Paulo | 939 |
| Rio de Janeiro | 127 |
| Minas Gerais | 121 |
| Paraná | 97 |
| Distrito Federal | 69 |
| Goiás | 67 |
| Bahia | 53 |
| Pernambuco | 47 |
| Santa Catarina | 42 |
| Espírito Santo | 34 |
| Rio Grande do Sul | 32 |
| Mato Grosso do Sul | 21 |
| Ceará | 18 |
| Mato Grosso | 16 |
| Rio Grande do Norte | 15 |
| Paraíba | 15 |
| Sergipe | 15 |
| Alagoas | 12 |
| Pará | 9 |
| Piauí | 7 |
| Maranhão | 7 |
| Tocantins | 5 |
| | <u>1,768</u> |

Raia Drogasil's stores are supplied by nine distribution centers located in seven States: São Paulo, Rio de Janeiro, Minas Gerais, Paraná, Goiás, Pernambuco and Bahia.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

The subsidiary 4Bio markets its products through telesales and delivery is made directly to the customer's location or through its three call centers in the states of São Paulo and Tocantins.

2. Presentation of quarterly information

The quarterly information was approved by the Executive Board on October 30, 2018.

The parent company and consolidated quarterly information is presented in thousands of Brazilian Reais (R\$), which is the Group's functional and presentation currency.

The Company's parent company and consolidated quarterly financial information for the periods ended September 30, 2018 and 2017 has been prepared in accordance with technical pronouncement CPC 21 (R1) - "Interim Financial Reporting", the requirements in Official Letter/CVM/SNC/SEP 003/2011 of April 28, 2011, and the International Financial Reporting Standards (IFRS) - IAS 34 and discloses all material information specific to the individual and consolidated quarterly information, and only such information, which is consistent with the information used by management in managing the activities.

The Company's financial statements for the year ended December 31, 2017 have been prepared in accordance with the accounting practices adopted in Brazil, including the rules issued by the Brazilian Securities and Exchange Commission (CVM) and the pronouncements issued by the Brazilian Accounting Pronouncements Committee (CPC), and are in conformity with the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB). The individual and consolidated quarterly information should be read in conjunction with the Company's financial statements for the year ended December 31, 2017.

The consolidated quarterly information includes the Company's quarterly information and the quarterly information of its subsidiary 4Bio. The consolidated quarterly information has been prepared in accordance with consolidation practices and applicable legal provisions. Therefore, the consolidated statements of income and of comprehensive income include three and nine months of operations of the Company and its Subsidiary, and the consolidated statements of cash flows and of value added include nine months of operations.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

The accounting practices adopted by the Subsidiary were applied uniformly and consistently with those adopted by the Company. Where applicable, all transactions, balances, income and expenses between the Subsidiary and the Company are fully eliminated in the consolidated quarterly information.

The quarterly information includes accounting estimates and requires management to exercise its judgment in the process of applying the Company's accounting policies regarding provision for estimated inventory losses, provision for the impairment of trade receivables, measurement of financial instruments, taxes recoverable, the amortization and depreciation periods for property and equipment and intangible assets, estimate of impairment of intangible assets with indefinite useful life, provision for legal claims, fair value measurement of financial liabilities, determination of provision for taxes, recognition of revenues from commercial agreements, among others. The significant estimates and judgments are disclosed in Note 4(w) to the financial statements for the year ended December 31, 2017.

The presentation of the parent company and consolidated statements of value added is required by the Brazilian corporate legislation and the accounting practices adopted in Brazil for listed companies. The IFRS do not require the presentation of this statement. Therefore, under the IFRS, such statement is presented as supplementary information to the set of the financial statements.

The Group adopted all standards, revised standards and interpretations issued by the CPC that were effective as at September 30, 2018.

3. New standards, amendments to and interpretations of existing standards

New or revised standards issued but not yet effective, i.e., that will become effective for annual periods beginning on or after January 1st, 2019:

- (i) IFRS 16 - Leases / CPC 6 (R2) - Leases: the new standard requires lessees to recognize the liability of future payments and the right of use of the leased assets for virtually all lease contracts, including operating leases. Certain short-term and low-value contracts may be out of the scope of this new standard. The Company's management hired an independent specialized company to assist in the identification of contracts (inventory of contracts), assessing whether it has or not lease agreements in accordance with IFRS 16 / CPC 06 (R2). The analysis is in process of evaluation of impacts, mainly in respect of lease of properties from third parties (context of payment with variable component) and future minimum payments of store leases (cancelable leases), whose amounts generated to this date are shown in Note 22. This refers to an aspect of the standard that contains a significant component of judgment and requires a careful evaluation and appropriate controls to measure the liabilities qualifying as lease agreements. As at September 30, 2018 the analyses and internal controls associated to the measurement and recognition of lease agreements are substantially completed and customized, pending for conclusion the definition of certain assumptions. Given the complexity of the application of the standard, and until it is applied on January 1, 2019, the conclusions may be changed.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

(ii) IFRIC 23 - Uncertainties related to the treatment of income tax: the interpretation clarifies how the recognition and measurement requirements of IAS 12 are applied when there are uncertainties about the treatment of income taxes (Corporate Income Tax - IRPJ and Social Contribution on Net Profit - CSLL). Management is assessing the impacts of these amendments.

There are no other IFRSs or IFRIC interpretations that are not yet effective that would be expected to have a material impact on the Group.

4. Significant accounting practices

The accounting practices adopted for preparing this ITR are consistent with those disclosed in Note 4 to the financial statements for the year ended December 31, 2017, except for the adjustment to the accounting policies to include the adoption of IFRS 9 / CPC 48 - Financial Instruments and IFRS 15 / CPC 47 - Revenue from Contracts with Customers, which were adopted by the Company as from January 1st, 2018, as shown below.

(a) IFRS 9 / CPC 48 – Financial Instruments - establishes requirements for the recognition and measurement of financial assets, financial liabilities and certain purchase and sale agreements of non-monetary items. This standard replaces CPC 38 / IAS 39 - Financial Instruments: Recognition and Measurement. IFRS 9 / CPC 48 includes mostly the requirements in CPC 38 / IAS 39 for the classification and measurement of financial liabilities. However, it eliminates prior categories of CPC 39 / IAS 39 for financial assets, namely, those held to maturity, loans and receivables and available for sale.

(i) Classification and measurement of financial assets and liabilities

In accordance with IFRS 9 / CPC 48 a financial asset is recognized on initial recognition as: at amortized cost; at fair value through other comprehensive income (FVTOCI) - debt instrument; FVTOCI - equity instrument; and at fair value through profit or loss (FVTPL). The classification of financial assets in accordance with IFRS 9 / CPC 48 is mainly based on the business model in which a financial asset is managed and on its characteristics of contractual cash flows. The new significant accounting policies are described as follows:

Financial assets at amortized cost - These assets are subsequently measured at amortized cost using the effective interest method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and losses are recognized in profit or loss. Any gain or loss on derecognition is recognized in profit or loss.

A financial asset is measured at amortized cost if it meets both the following conditions and is not designated as measured at FVTPL:

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

- is held within a business model whose objective is to hold financial assets to receive contractual cash flows; and
- its contractual terms generate, on specific dates, cash flows that are related to the payment of principal and interest on the outstanding principal amount.

A debt instrument is measured at FVTOCI if it meets both the following conditions and is not designated as measured at FVTPL:

- is held within a business model whose objective is achieved both through the collection of contractual cash flows and through the sale of financial assets; and
- its contractual terms generate, on specific dates, cash flows that are solely payment of principal and interest on the outstanding principal amount.

Financial assets at FVTPL are subsequently measured at fair value. The net gain or loss, including interest or dividend income, is recognized in profit or loss.

Debt instruments at FVTOCI are subsequently measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment losses are recognized in profit or loss. Other net gains or losses are recognized in OCI. On derecognition, the accumulated gain or loss in OCI is reclassified to profit or loss.

All financial assets not classified as measured at amortized cost or FVTOCI, as described above, are classified as FVTPL. This includes all derivative financial assets. On initial recognition, the Company may designate irrevocably a financial asset that otherwise meets the requirements to be measured at amortized cost or as FVTOIC or FVTPL, if this eliminates or significantly reduces an accounting mismatch that would otherwise arise (fair value option available in IFRS 9 / CPC 48).

A financial asset (except trade receivables without a significant financial component that is initially measured at the transaction price) is initially measured at fair value, plus, for an item not measured at FVTPL, the transaction costs that are directly attributable to its acquisition.

The Company's financial assets comprise mainly investments in debentures held under repurchase agreements restated based on the variation of the Interbank Deposit Certificate - CDI rates (Note 5), trade receivables, represented almost entirely by receivables from credit and debit cards (Note 6), both classified as subsequently measured at amortized cost. The adoption of CPC 48 / IFRS 9 did not result in significant changes in the Company's accounting policies.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

The Company's financial liabilities refer mainly to financing contracted through operations with BNDES (Brazilian Economic and Social Development Bank) and debentures issued by the Company (Note 12), which are classified as subsequently measured at amortized cost. Regarding financial liabilities, the adoption of IFRS 9 / CPC 48 did not result in significant changes in the Company's accounting policies.

(ii) Impairment losses

Expected credit losses are estimates weighted by the probability of credit losses based on the history of losses and the projections of related assumptions. Credit losses are measured at present value based on all cash deficits (that is, the difference between the cash flows due to the Company according to the contract and the cash flows that the Company expects to receive). Expected credit losses are discounted at the effective interest rate of the financial asset.

In conformity with the replacement of the incurred loss model for the expected loss model, Management concluded that the methodology already adopted is in compliance with the expected loss model and, therefore, the first time adoption of IFRS 9 / CPC 48 beginning on January 1, 2018 did not have significant impact on the measurement of the provision for impairment of trade receivables since a significant part of the trade receivables balance refers to credit and debit cards.

(iii) Hedge accounting

The Company adopts the policy of not operating with derivative financial instruments, except in specific situations of equipment imports, which are hedged by firm commitments, and the change in the fair value of the compensation between the item and the instrument is recognized directly in profit or loss. The first-time adoption of IFRS 9 / CPC 48 on January 1, 2018 did not have material impacts related to derivative financial instruments.

Management assessed the new standard and, in its opinion, it did not have material impact on its financial statements, considering the nature of its main financial transactions.

Transition - the changes in accounting policies arising from the adoption of IFRS 9 / CPC 48 were applied retrospectively, however, without significant changes on the transition date.

(b) IFRS 15 / CPC 47 - Revenue from Contracts with Customers: this standard addresses the new approach to revenue recognition from transactions with customers. The standard establishes criteria of when and how much revenue should be recognized as from the identification of the performance obligations, the transfer of control of the product or service to the customer and the determination of the sale price.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

The Company opted for the modified retrospective application of IFRS 15/ CPC 47, effective January 1st, 2018.

This standard establishes a model that aims to identify whether the criteria for revenue recognition have been satisfied and comprise the following aspects:

- (i) Identification of a contract with a customer;
- (ii) Determination of the performance obligations;
- (iii) Determination of the transaction price;
- (iv) Allocation of the transaction price; and
- (v) Recognition of revenue at a point in time or over time, in accordance with the fulfillment of the performance obligations.

Being a Company that operates in the retail industry of medicines, where the consumer self-service the products at our stores where prices and discounts are informed by consulting the Company's employees or obtained in places where the products are exposed and considering that the transfer of control processes take place when delivering directly to the final consumer at the points of sales, it was concluded that there is a single performance obligation and, therefore, there is no complexity involved in defining performance obligations and transferring control of products and services to consumers.

Additionally, the other transactions of the Company subject to the assessment under IFRS 15 / CPC 47 are represented by variable considerations associated to commercial agreements where products can be sold together with other products or with discounts, which are substantially negotiations promoted by suppliers at the Company's points of sale. The sales revenue recognized in the financial statements comprises the fair value of the transactions carried out that, according to the nature of the negotiations, consider amounts of sales and receipts from consumers supplemented by receipts from suppliers.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

5. Cash and cash equivalents

| | <u>Parent Company</u> | | <u>Consolidated</u> | |
|---|-----------------------|-----------------|---------------------|-----------------|
| | <u>Sep-2018</u> | <u>Dec-2017</u> | <u>Sep-2018</u> | <u>Dec-2017</u> |
| Cash and banks | 82,478 | 81,738 | 83,052 | 82,118 |
| Investment fund | 278 | 90,769 | 278 | 90,769 |
| Bank Deposit Certificates (CDBs) | 21,830 | | 21,830 | |
| Debentures held under repurchase agreements | 165,810 | 83,404 | 168,395 | 91,986 |
| | <u>270,396</u> | <u>255,911</u> | <u>273,555</u> | <u>264,873</u> |

Investments in Bank Deposit Certificates and debentures held under repurchase agreements have high liquidity and are restated based on the variations of the CDI rate, and reflect the realizable value, without risk of change in value or loss of income.

For debentures held under repurchase agreements, the financial institutions which negotiated these securities guarantee credit risk and immediate liquidity without loss of income. The financial investments are concentrated at the banks Bradesco, Santander, Itaú and Banco do Brasil.

The investments in Bank Deposit Certificates have a grace period of 30 days and are adjusted by the variation of the CDI rate.

The Company's exposure to interest rate risks on financial investments is disclosed in Note 23b.

6. Customers

| | <u>Parent Company</u> | | <u>Consolidated</u> | |
|---|-----------------------|-----------------|---------------------|-----------------|
| | <u>Sep-2018</u> | <u>Dec-2017</u> | <u>Sep-2018</u> | <u>Dec-2017</u> |
| Trade receivables | 924,210 | 841,471 | 1,043,149 | 934,735 |
| (-) Provision for impairment of trade receivables | <u>(1,233)</u> | <u>(3,889)</u> | <u>(2,028)</u> | <u>(4,664)</u> |
| | <u>922,977</u> | <u>837,582</u> | <u>1,041,121</u> | <u>930,071</u> |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

The ageing of trade receivables is as follows:

| | <u>Parent Company</u> | | <u>Consolidated</u> | |
|---|-----------------------|-----------------|---------------------|-----------------|
| | <u>Sep-2018</u> | <u>Dec-2017</u> | <u>Sep-2018</u> | <u>Dec-2017</u> |
| Not yet due | 902,418 | 831,006 | 1,015,482 | 919,711 |
| Overdue | | | | |
| Between 1 to 30 days | 19,320 | 4,497 | 22,263 | 5,895 |
| Between 31 to 60 days | 1,016 | 1,949 | 1,718 | 2,364 |
| Between 61 to 90 days | 485 | 505 | 1,218 | 988 |
| Between 91 to 180 days | 923 | 3,514 | 1,941 | 4,306 |
| Between 181 to 360 days | 48 | | 527 | 1,471 |
| Provision for impairment of trade receivables | <u>(1,233)</u> | <u>(3,889)</u> | <u>(2,028)</u> | <u>(4,664)</u> |
| | <u>922,977</u> | <u>837,582</u> | <u>1,041,121</u> | <u>930,071</u> |

Days sales outstanding, represented by credit and debit cards and partnerships with companies and the government, are approximately 40 days, term that is considered part of the normal conditions inherent in the Company's operations. A substantial part of the amounts overdue for more than 31 days are represented by collection through special plans and PBMs.

The changes in the Company's provision for the impairment of trade receivables are as follows:

| | <u>Parent Company</u> | | <u>Consolidated</u> | |
|------------------|-----------------------|-----------------|---------------------|-----------------|
| | <u>Sep-2018</u> | <u>Dec-2017</u> | <u>Sep-2018</u> | <u>Dec-2017</u> |
| Opening balance | (3,889) | (2,612) | (4,664) | (2,756) |
| Additions | (4,245) | (9,967) | (6,548) | (13,629) |
| Reversals/Losses | <u>6,901</u> | <u>8,690</u> | <u>9,184</u> | <u>11,721</u> |
| Closing balance | <u>(1,233)</u> | <u>(3,889)</u> | <u>(2,028)</u> | <u>(4,664)</u> |

Trade receivables are classified as financial assets at amortized cost and are therefore measured as described in Note 4(a)(i) above.

The reversals/losses at September 30, 2018 are comprised of R\$ 5,294 (losses) and R\$ 1,607 (reversals) for the parent Company and R\$ 5,698 (losses) and R\$ 3,486 (reversals) for the consolidated accounts.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

7. Inventory

| | <u>Parent Company</u> | | <u>Consolidated</u> | |
|--------------------------------|-----------------------|------------------|---------------------|------------------|
| | <u>Sep-2018</u> | <u>Dec-2017</u> | <u>Sep-2018</u> | <u>Dec-2017</u> |
| Goods for resale | 2,750,778 | 2,490,941 | 2,801,504 | 2,529,596 |
| Goods held by third parties | 16,297 | | 16,297 | |
| Materials | 1,886 | 1,819 | 1,886 | 1,819 |
| Provision for inventory losses | <u>(12,785)</u> | <u>(13,821)</u> | <u>(12,785)</u> | <u>(13,821)</u> |
| Total inventory | <u>2,756,176</u> | <u>2,478,939</u> | <u>2,806,902</u> | <u>2,517,594</u> |

Changes in the provision for goods losses are as follows:

| | <u>Parent Company</u> | | <u>Consolidated</u> | |
|-----------------|-----------------------|-----------------|---------------------|-----------------|
| | <u>Sep-2018</u> | <u>Dec-2017</u> | <u>Sep-2018</u> | <u>Dec-2017</u> |
| Opening balance | (13,821) | (10,165) | (13,821) | (10,165) |
| Additions | (1,890) | (8,954) | (1,890) | (8,954) |
| Write-offs | <u>2,926</u> | <u>5,298</u> | <u>2,926</u> | <u>5,298</u> |
| Closing balance | <u>(12,785)</u> | <u>(13,821)</u> | <u>(12,785)</u> | <u>(13,821)</u> |

For the quarter ended September 30, 2018, cost of sales recognized in the statement of income was R\$ 2,476,118 (R\$ 2,279,288 - 3rd quarter/2017) for the parent company and R\$ 2,640,038 (R\$ 2,396,444 - 3rd quarter/2017) for the consolidated accounts, including the amount of the write-offs of goods inventories recognized as losses for the quarter amounting to R\$ 21,455 (R\$ 21,927 - 3rd quarter/2017) for the parent company and R\$ 21,563 (R\$ 21,969 - 3rd quarter/2017) for the Consolidated accounts.

The effect of the recognition, reversal or write-off of the provision for inventory losses is included in cost of sales in the statement of income.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

8. Taxes recoverable

| | Parent Company | | Consolidated | |
|--|----------------|----------------|----------------|----------------|
| | Sep-2018 | Dec-2017 | Sep-2018 | Dec-2017 |
| Taxes on profit recoverable | | | | |
| Withholding Income Tax (IRRF) | 1,001 | 440 | 1,001 | 440 |
| Corporate Income Tax (IRPJ) | 10,827 | 214 | 10,827 | 214 |
| Social Contribution on Net Profit (CSLL) | 3,922 | | 3,922 | |
| | <u>15,750</u> | <u>654</u> | <u>15,750</u> | <u>654</u> |
| Other taxes recoverable | | | | |
| Value Added Tax on Sales and Services (ICMS) - credit balance | 37,988 | 57,661 | 41,056 | 58,350 |
| ICMS - Refund of ICMS withheld in advance | 148 | 320 | 148 | 320 |
| ICMS on acquisitions of fixed assets | 50,759 | 43,250 | 50,759 | 43,250 |
| Social Integration Program (PIS) | 956 | 892 | 956 | 892 |
| Social Contribution on Revenue (COFINS) | 4,404 | 4,108 | 4,404 | 4,109 |
| Social Investment Fund - 1982 - securities issued to cover court-ordered debts | 561 | 561 | 561 | 561 |
| National Institute of Social Security (INSS) | | 3,617 | | 3,617 |
| | <u>94,816</u> | <u>110,409</u> | <u>97,884</u> | <u>111,099</u> |
| | <u>110,566</u> | <u>111,063</u> | <u>113,634</u> | <u>111,753</u> |
| Current assets | 71,959 | 78,088 | 75,027 | 78,778 |
| Non-current assets | 38,607 | 32,975 | 38,607 | 32,975 |

The ICMS credits amounting to R\$ 37,988 and R\$ 148 (R\$ 57,661 and R\$ 320 - Dec-2017) for the parent company and R\$ 41,056 and R\$ 148 (R\$ 58,350 and R\$ 320 - Dec-2017) for the consolidated accounts are the result of applying different ICMS rates and of refunds of ICMS-ST (the substitute taxpayer regime) on goods receiving and shipping operations carried out by the Company's distribution centers in the states of São Paulo, Paraná and Pernambuco, in order to supply its branches located in other Brazilian states. The respective tax credits have been progressively consumed in the last months, mainly due to goods that are not under the substitute taxpayer regime.

The Group analyzed the use of ICMS credits and concluded that the tax credit balances will be used within 12 months. As regards ICMS credits on purchases of property, plant and equipment, these credits will be utilized in up to 48 months according to the legislation in force.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

9. Investments

(a) Business combinations

In 2015, the Company acquired a 55% equity interest in 4Bio Medicamentos S.A. ("4Bio") and obtained its controlling interest on October 1, 2015.

The Agreement establishes the granting of call and put options for all the remaining shares (45% of total shares) held by the founding stockholders after January 2021, and the exercise price will be calculated based on the average of the adjusted EBITDA of 4Bio for the years ending December 31, 2018, 2019 and 2020 the fair value of which at September 30, 2018 corresponds to R\$ 51,674 (R\$ 47,515 - Dec-2017).

The fair value of the additional stock options recorded in Parent Company and Consolidated, of R\$ 51,674 (R\$ 47,515 - Dec-2017) is classified as Level 3 in the fair value hierarchy. The main fair value measurements have as reference: (i) a discount rate of 11.84% in Dec-2017 (22.04% - Dec-2016), (ii) an average growth rate of EBITDA of 50.46% in Dec-2017 (27.4% in Dec-2016), considering the average of the EBITDAs projected for 2018 to 2020 and the multiple provided for in contract.

The goodwill of R\$ 25,563 arising from the acquisition represents the future economic benefits expected from the business combination.

(b) Changes in investments

At September 30, 2018 and 2017, the Company's investment balance is as follows:

| <u>Company name</u> | <u>Main activity</u> | <u>Interest (%)</u> | <u>9/30/2018</u> | <u>9/30/2017</u> |
|------------------------|-----------------------------|---------------------|------------------|------------------|
| 4Bio Medicamentos S.A. | Retail of special medicines | 55% | 34,677 | 31,200 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

Changes in the investment balance in the subsidiary, presented in the parent company financial statements, are as follows:

| | Parent Company | |
|---|----------------|----------|
| | Sep-2018 | Sep-2017 |
| At January 1 | 31,489 | 29,424 |
| Increase in ownership interests in subsidiary | 229 | 471 |
| Equity in the results of subsidiary | 2,959 | 1,305 |
| Closing balance | 34,677 | 31,200 |

For the purposes of calculating the equity of 4Bio Medicamentos S.A., the Company has adjusted the assets, liabilities and related changes in the statement of income of 4Bio based on the allocation of purchase price at the acquisition date. The table below shows the effects on the profit for the period of 4Bio for the purposes of determining the equity at September 30, 2018:

| | Parent Company | |
|---|-----------------|-----------------|
| | Sep-2018 | Sep-2017 |
| Result of 4Bio (nine-month period) | 3,390 | 1,735 |
| Amortization of surplus arising from the business combination | (431) | (430) |
| Adjusted profit for the period of 4Bio | 2,959 | 1,305 |
| Adjusted equity | Sep-2018 | Sep-2017 |
| Investment at book value (55%) | 18,773 | 14,723 |
| Allocation of the purchase price (surplus of assets) | 4,541 | 5,410 |
| Deferred income tax liability on allocation adjustments | (1,544) | (1,840) |
| | 21,770 | 18,293 |
| Goodwill based on expected future profitability | 12,907 | 12,907 |
| | 34,677 | 31,200 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

10. Property and equipment and intangible assets

I. Property and equipment

Changes in the parent company's property and equipment are as follows:

| | | | | | | | 2018 | 2017 | |
|---|---------------|-----------------|--|----------------------------|-----------------|---------------------------|--|------------------|------------------|
| | Land | Buildings | Furniture, fittings and facilities | Machinery and equipment | Vehicles | Leasehold improvements | Store renovation and modernization | Total | Total |
| Cost | | | | | | | | | |
| At January 1 | 27,440 | 41,917 | 642,058 | 367,753 | 59,183 | 977,427 | 3,863 | 2,119,641 | 1,664,892 |
| Additions | | | 119,891 | 51,127 | 3,618 | 245,201 | | 419,837 | 404,727 |
| Disposals and write-offs | | | (6,793) | (3,429) | (149) | (98,951) | | (109,322) | (71,064) |
| Provision (reversal) for store closures | | | 388 | | | 2,429 | | 2,817 | 3,388 |
| At September 30 | <u>27,440</u> | <u>41,917</u> | <u>755,544</u> | <u>415,451</u> | <u>62,652</u> | <u>1,126,106</u> | <u>3,863</u> | <u>2,432,973</u> | <u>2,001,943</u> |
| Accumulated depreciation | | | | | | | | | |
| Average annual depreciation rates (%) | | 2.5 - 2.7 | 7.4 - 10 | 7.1 - 15.8 | 20.0 - 23.7 | 17.0 - 21.6 | 20.0 | | |
| At January 1 | | (20,985) | (221,374) | (170,137) | (16,711) | (412,800) | (3,721) | (845,728) | (660,001) |
| Additions | | (813) | (48,456) | (36,960) | (5,252) | (153,732) | (129) | (245,342) | (196,329) |
| Disposals and write-offs | | | 5,082 | 3,072 | 82 | 95,265 | | 103,501 | 65,960 |
| Provision (reversal) for store closures | | | (124) | | | (1,520) | | (1,644) | (1,048) |
| At September 30 | | <u>(21,798)</u> | <u>(264,872)</u> | <u>(204,025)</u> | <u>(21,881)</u> | <u>(472,787)</u> | <u>(3,850)</u> | <u>(989,213)</u> | <u>(791,418)</u> |
| Net balance | | | | | | | | | |
| At January 1 | <u>27,440</u> | <u>20,932</u> | <u>420,684</u> | <u>197,616</u> | <u>42,472</u> | <u>564,627</u> | <u>142</u> | <u>1,273,913</u> | <u>1,004,891</u> |
| At September 30 | <u>27,440</u> | <u>20,119</u> | <u>490,672</u> | <u>211,426</u> | <u>40,771</u> | <u>653,319</u> | <u>13</u> | <u>1,443,760</u> | <u>1,210,525</u> |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

Changes in the consolidated property and equipment are as follows:

| | | | | | | | 2018 | 2017 | |
|---|---------------|-----------------|--|----------------------------|-----------------|---------------------------|--|------------------|------------------|
| | Land | Buildings | Furniture, fittings and facilities | Machinery and equipment | Vehicles | Leasehold improvements | Store renovation and modernization | Total | Total |
| Cost | | | | | | | | | |
| At January 1 | 27,440 | 41,917 | 643,187 | 368,944 | 59,436 | 978,649 | 3,863 | 2,123,436 | 1,667,614 |
| Additions | | | 120,045 | 51,382 | 3,618 | 245,618 | | 420,663 | 405,669 |
| Disposals and write-offs | | | (6,793) | (3,429) | (149) | (98,951) | | (109,322) | (71,064) |
| Provision (reversal) for store closures | | | 388 | | | 2,429 | | 2,817 | 3,389 |
| At September 30 | <u>27,440</u> | <u>41,917</u> | <u>756,827</u> | <u>416,897</u> | <u>62,905</u> | <u>1,127,745</u> | <u>3,863</u> | <u>2,437,594</u> | <u>2,005,608</u> |
| Accumulated depreciation | | | | | | | | | |
| Average annual depreciation rates (%) | | 2.5 - 2.7 | 7.4 - 10 | 7.1 - 15.8 | 20 - 23.7 | 17 - 21.6 | 20 | | |
| At January 1 | | (20,985) | (221,731) | (170,611) | (16,913) | (413,199) | (3,721) | (847,160) | (661,008) |
| Additions | | (813) | (48,538) | (37,101) | (5,264) | (153,914) | (129) | (245,759) | (196,628) |
| Disposals and write-offs | | | 5,082 | 3,072 | 82 | 95,265 | | 103,501 | 65,960 |
| Provision (reversal) for store | | | (124) | | | (1,520) | | (1,644) | (1,048) |
| At September 30 | | <u>(21,798)</u> | <u>(265,311)</u> | <u>(204,640)</u> | <u>(22,095)</u> | <u>(473,368)</u> | <u>(3,850)</u> | <u>(991,062)</u> | <u>(792,724)</u> |
| Net balance | | | | | | | | | |
| At January 1 | 27,440 | 20,932 | 421,456 | 198,333 | 42,523 | 565,450 | 142 | 1,276,276 | 1,006,606 |
| At September 30 | <u>27,440</u> | <u>20,119</u> | <u>491,516</u> | <u>212,257</u> | <u>40,810</u> | <u>654,377</u> | <u>13</u> | <u>1,446,532</u> | <u>1,212,884</u> |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

II. Intangible assets

Changes in the Company's intangible assets are as follows:

| | <u>2018</u> | | | | | | | <u>2017</u> | |
|---|-----------------------|--|---|--|------------------------|----------------------------|--------------------------------|------------------|------------------|
| | <u>Points of sale</u> | <u>Software license and systems implementation</u> | <u>Goodwill on acquisition (Vison Ltda)</u> | <u>Goodwill on acquisition (Raia S.A.)</u> | <u>Trademarks</u> | <u>Customers portfolio</u> | <u>Other intangible assets</u> | <u>Total</u> | <u>Total</u> |
| Cost | | | | | | | | | |
| At January 1 | 266,379 | 109,542 | 22,275 | 780,084 | 151,700 | 41,700 | 6,654 | 1,378,334 | 1,328,006 |
| Additions | 36,402 | 28,276 | | | | | 609 | 65,287 | 62,339 |
| Disposals and write-offs | (27,692) | (5,908) | | | | | | (33,600) | (28,566) |
| Provision (reversal) for store closures | 200 | 3 | | | | | | 203 | (2) |
| At September 30 | <u>275,289</u> | <u>131,913</u> | <u>22,275</u> | <u>780,084</u> | <u>151,700</u> | <u>41,700</u> | <u>7,263</u> | <u>1,410,224</u> | <u>1,361,777</u> |
| Accumulated amortization | | | | | | | | | |
| Average annual amortization rates (%) | 17.0 - 23.4 | 20 | Indefinite useful life | Indefinite useful life | Indefinite useful life | 6.7 - 25 | 20 | | |
| At January 1 | (138,359) | (44,493) | (2,387) | | | (37,637) | | (222,876) | (190,727) |
| Additions | (36,429) | (17,935) | | | | (345) | | (54,709) | (47,890) |
| Disposals and write-offs | 26,123 | 5,902 | | | | | | 32,025 | 28,026 |
| Provision (reversal) for store | (143) | (2) | | | | | | (145) | 1 |
| At September 30 | <u>(148,808)</u> | <u>(56,528)</u> | <u>(2,387)</u> | | | <u>(37,982)</u> | | <u>(245,705)</u> | <u>(210,590)</u> |
| Net balance | | | | | | | | | |
| At January 1 | 128,020 | 65,049 | 19,888 | 780,084 | 151,700 | 4,063 | 6,654 | 1,155,458 | 1,137,279 |
| At September 30 | <u>126,481</u> | <u>75,385</u> | <u>19,888</u> | <u>780,084</u> | <u>151,700</u> | <u>3,718</u> | <u>7,263</u> | <u>1,164,519</u> | <u>1,151,187</u> |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

Changes in the consolidated intangible assets are as follows:

| | | | | | | | | | | | 2018 | 2017 | |
|---|------------------|---|--------------------------------------|-------------------------------------|--------------------------------|------------------------|-----------------|-------------------------------|-----------------------------|---------------------------|-------------------------|------------------|------------------|
| | Points of sale | Software license and systems implementation | Goodwill on acquisition (Vison Ltda) | Goodwill on acquisition (Raia S.A.) | Goodwill on acquisition (4BIO) | Trademarks Raia S.A | Trademarks 4BIO | Customers portfolio Raia S.A. | Customers relationship 4BIO | Distribution channel 4BIO | Other intangible assets | Total | Total |
| Cost | | | | | | | | | | | | | |
| At January 1 | 266,379 | 110,426 | 22,275 | 780,084 | 25,563 | 151,700 | 5,069 | 41,700 | 7,928 | 535 | 6,722 | 1,418,381 | 1,367,584 |
| Additions | 36,402 | 28,499 | | | | | | | | | 969 | 65,870 | 62,630 |
| Disposals and write-offs | (27,692) | (5,908) | | | | | | | | | | (33,600) | (28,566) |
| Provision (reversal) for store closures | 200 | 3 | | | | | | | | | | 203 | (2) |
| At September 30 | <u>275,289</u> | <u>133,020</u> | <u>22,275</u> | <u>780,084</u> | <u>25,563</u> | <u>151,700</u> | <u>5,069</u> | <u>41,700</u> | <u>7,928</u> | <u>535</u> | <u>7,691</u> | <u>1,450,854</u> | <u>1,401,646</u> |
| Accumulated amortization | | | | | | | | | | | | | |
| Average annual amortization rates (%) | 17 - 23.4 | 20 | Indefinite useful life | Indefinite useful life | Indefinite useful life | Indefinite useful life | 20 | 6.7 - 25 | 7 | 0.3 | 20 | | |
| At January 1 | (138,359) | (44,824) | (2,387) | | | | (2,281) | (37,637) | (1,274) | (535) | (68) | (227,365) | (193,528) |
| Additions | (36,429) | (18,055) | | | | | (760) | (345) | (425) | | (50) | (56,064) | (49,147) |
| Disposals and write-offs | 26,123 | 5,903 | | | | | | | | | | 32,026 | 28,026 |
| Provision (reversal) for store | (143) | (2) | | | | | | | | | | (145) | 1 |
| At September 30 | <u>(148,808)</u> | <u>(56,978)</u> | <u>(2,387)</u> | | | | <u>(3,041)</u> | <u>(37,982)</u> | <u>(1,699)</u> | <u>(535)</u> | <u>(118)</u> | <u>(251,548)</u> | <u>(214,648)</u> |
| Net balance | | | | | | | | | | | | | |
| At January 1 | <u>128,020</u> | <u>65,602</u> | <u>19,888</u> | <u>780,084</u> | <u>25,563</u> | <u>151,700</u> | <u>2,788</u> | <u>4,063</u> | <u>6,654</u> | | <u>6,654</u> | <u>1,191,016</u> | <u>1,174,056</u> |
| At September 30 | <u>126,481</u> | <u>76,042</u> | <u>19,888</u> | <u>780,084</u> | <u>25,563</u> | <u>151,700</u> | <u>2,028</u> | <u>3,718</u> | <u>6,229</u> | | <u>7,573</u> | <u>1,199,306</u> | <u>1,186,998</u> |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

(i) Goodwill on acquisition of companies

The goodwill arising on acquisition of companies is tested annually for impairment.

Goodwill on acquisition of Drogaria Vison Ltda.

Goodwill of R\$ 19,888 relates to the acquisition of Drogaria Vison Ltda. on February 13, 2008, which was merged into the Company as from June 30, 2008.

The goodwill is based on the expected future profitability, as assessed by an independent expert, and was amortized from April to December 2008. As provided for in CPC Guidance (OCPC) 02, beginning in 2009, goodwill is no longer amortized, but is tested annually for impairment.

Goodwill on acquisition of Raia S.A.

The Company recorded goodwill of R\$ 780,084 arising from the business combination with Raia S.A., which occurred on November 10, 2011, based on the expected future profitability arising from the difference between the amounts of assets assigned and received.

Goodwill on acquisition of 4Bio Medicamentos S.A.

The Company recorded goodwill of R\$ 25,563 arising from the business combination with 4Bio Medicamentos S.A., which occurred on October 1, 2015, whose amount was supplemented by the final adjustment of the price at March 31, 2016 of R\$ 2,040, which is based on expected future profitability arising from the difference between the amounts of assets assigned and received.

11. Employee benefits

(a) Profit sharing program

The Group has a profit sharing program intended mainly to measure the performance of employees during the year. On a monthly basis, a liability and an expense for profit sharing are recognized in the statement of income based on estimates of achievement of operating targets and specific objectives established and approved by Management. The recognition as liabilities is made in the account of salaries and social charges and in the statement of income the recognition is made in the account of selling expenses and general and administrative expenses (Note 18).

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

(b) Other benefits

Other short-term benefits are also granted to employees, such as life insurance, health and dental care, housing allowance, maternity leave and scholarship, which are recognized on an accrual basis and whose right is extinguished at the end of the employment relationship with the Group.

The Group does not grant post-employment benefits, severance pay benefits or other long-term benefits.

12. Borrowing

| | Average annual long-term interest rate | Parent Company | | Consolidated | |
|-----------------------------------|--|----------------|----------------|----------------|----------------|
| | | Sep-2018 | Dec-2017 | Sep-2018 | Dec-2017 |
| BNDES - Sub-loan | | | | | |
| Businesses | TJLP + 2.13% (+2.23% - Dec/2017) p.a. | 76,919 | 109,387 | 76,919 | 109,387 |
| Businesses | SELIC + 2.35% (2.34% - Dec/2017) p.a. | 90,128 | 115,633 | 90,128 | 115,633 |
| Machinery, equipment and vehicles | Fixed rate (3.52% - Dec/2017) p.a. | | 914 | | 914 |
| Machinery, equipment and vehicles | TJLP + 2.02% (2.02% - Dec/2017) p.a. | 12,969 | 16,690 | 12,969 | 16,690 |
| Machinery, equipment and vehicles | PSI + 9.54% (9.54% - Dec/2017) p.a. | 3,005 | 4,301 | 3,005 | 4,301 |
| Machinery, equipment and vehicles | SELIC + 2.42% (2.42% - Dec/2017) p.a. | 57 | 71 | 57 | 71 |
| Working capital | SELIC + 2.42% (2.37% - Dec/2017) p.a. | 26,155 | 58,359 | 26,155 | 58,359 |
| Other | | 2,253 | 2,448 | 2,253 | 2,448 |
| Debentures | | | | | |
| 1st issue of debentures | 104.75% of CDI | 273,961 | 303,156 | 273,961 | 303,156 |
| 2nd issue of debentures | 104.50% of CDI | 411,271 | | 411,271 | |
| Borrowing | | | | | |
| Other | | | | 6,408 | |
| | | <u>896,718</u> | <u>610,959</u> | <u>903,126</u> | <u>610,959</u> |
| Current liabilities | | 230,797 | 196,248 | 237,205 | 196,248 |
| Non-current liabilities | | 665,921 | 414,711 | 665,921 | 414,711 |

Characteristics of the borrowing

Borrowing from the BNDES is used for the expansion of stores, acquisition of machinery/equipment, vehicles and also to finance the Company's working capital.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

The subloans for the Social Project, Development of Own Brand and Acquisition of National Software are grouped in the Others line. Part of the Company's borrowing from BNDES has been taken out in the form of sub-loans, totaling R\$ 211,486 (R\$ 307,803 - Dec-2017), subject to the following restrictive covenants:

- (i) Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) margin (EBITDA/Net operating revenue): equal to or higher than 3.6% and
- (ii) Total net debt/Total assets: equal to or lower than 20%.

Covenants are measured annually and, at December 31, 2017, the Company was in compliance with these covenants.

If these requirements were not met, the Company would have to provide BNDES with bank guarantees to ensure the performance of its obligations under the agreement.

The Group is not a party to any agreements containing non-financial covenants.

Non-current amounts mature as follows:

| | <u>Parent Company</u> | <u>Consolidated</u> |
|---------------------|---------------------------|---------------------|
| | <u>Sep-2018</u> | <u>Sep-2018</u> |
| 2019 | 95,400 | 95,400 |
| 2020 | 220,041 | 220,041 |
| 2021 | 183,928 | 183,928 |
| 2022 and thereafter | 166,552 | 166,552 |
| | <u>665,921</u> | <u>665,921</u> |

Characteristics of the debentures

On April 2nd, 2018, the Company performed the 2nd issuance of debentures:

| <u>Type of issue</u> | <u>Issue amount</u> | <u>Quantity outstanding</u> | <u>Issue</u> | <u>Maturity</u> | <u>Annual charges</u> | <u>Unit price</u> |
|-------------------------|---------------------|---------------------------------|--------------|-----------------|---------------------------|-------------------|
| 2nd issue – 9 series | R\$ 400,000 | 40,000 | 4/2/2018 | 2018-2023 | 104.5% * | R\$ 10 |

* Weighted average rate of series.

The debentures were issued in April 2018 and have maturity of 60 months (April/2023), except for the assumptions of early maturity, as per the clauses of the indenture.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

The costs incurred on the issues of the Company's two debentures (2017 - 1st issue and 2018 - 2nd issue), including fees, commissions and other costs, totaled R\$ 2,115 and are classified in the line item of the respective debentures and are being recognized over the total period of the debt. At September 30, 2018, the amount to be recognized was R\$ 1,445, and is presented net in the debentures balance.

The amortization of the principal related to the 2nd issuance of debentures will occur in 9 semiannual consecutive installments, the first being from the 12nd month after the issue. The payment of the remuneration will occur on a semiannual basis, and the first payment is due in April 2019, and other payments always in April and October of each year, until the due date.

The characteristics of the debentures issued in 2017 were not changed, as shown in the table below:

| Type of issue | Issue amount | Quantity outstanding | Issue | Maturity | Annual charges | Unit price |
|---------------------------|--------------|----------------------|-----------|-------------|----------------|------------|
| 1st issue – single series | R\$ 300,000 | 30,000 | 4/19/2017 | 2017 - 2022 | 104.75% | 10 |

The Company's debentures are conditioned to the compliance with the following covenants:

(i) Net Debt / EBITDA: cannot exceed 3.0 times.

Covenants are measured quarterly and, at September 30, 2018, the Company was in compliance with these covenants.

The non-compliance with the covenants for two consecutive quarters can be considered as a default event and consequently result in early maturity.

Reconciliation of net debt

Changes in the net debt are as follows:

| | Parent Company | | Consolidated | |
|---------------------------|----------------|-----------|--------------|-----------|
| | Sep-2018 | Dec-2017 | Sep-2018 | Dec-2017 |
| Short-term borrowings | 230,797 | 196,248 | 237,205 | 196,248 |
| Long-term borrowings | 665,921 | 414,711 | 665,921 | 414,711 |
| Total debt | 896,718 | 610,959 | 903,126 | 610,959 |
| Cash and cash equivalents | (270,396) | (255,911) | (273,555) | (264,873) |
| Net debt | 626,322 | 355,048 | 629,571 | 346,086 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

| | Parent Company | | | |
|---------------------------------------|----------------|----------------|---------------------------|----------------|
| | Borrowing | Total debt | Cash and cash equivalents | Net debt |
| Net debt at January 1, 2018 | 610,959 | 610,959 | (255,911) | 355,048 |
| Capital contribution | 400,587 | 400,587 | | 400,587 |
| Accrued interest | 42,583 | 42,583 | | 42,583 |
| Payment of interest | (19,708) | (19,708) | | (19,708) |
| Amortization of principal | (134,820) | (134,820) | | (134,820) |
| Transaction cost | (2,883) | (2,883) | | (2,883) |
| Increase in cash and cash equivalents | | | (14,485) | (14,485) |
| Net debt at September 30, 2018 | <u>896,718</u> | <u>896,718</u> | <u>(270,396)</u> | <u>626,322</u> |

| | Consolidated | | | |
|---------------------------------------|----------------|----------------|---------------------------|----------------|
| | Borrowing | Total debt | Cash and cash equivalents | Net debt |
| Net debt at January 1, 2018 | 610,959 | 610,959 | (264,873) | 346,086 |
| Capital contribution | 406,960 | 406,960 | | 406,960 |
| Accrued interest | 42,618 | 42,618 | | 42,618 |
| Payment of interest | (19,708) | (19,708) | | (19,708) |
| Amortization of principal | (134,820) | (134,820) | | (134,820) |
| Transaction cost | (2,883) | (2,883) | | (2,883) |
| Increase in cash and cash equivalents | | | (8,682) | (8,682) |
| Net debt at September 30, 2018 | <u>903,126</u> | <u>903,126</u> | <u>(273,555)</u> | <u>629,571</u> |

13. Provision for contingencies and judicial deposits

The Company and its subsidiary are subject to legal claims (tax, civil and labor) arising in the normal course of business. Management, supported by the opinion of its legal advisors and, where applicable, by specific opinions issued by experts, assesses the probable final outcomes of ongoing litigation and determines whether or not setting up of provision for contingencies is necessary.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

At September 30, 2018 and December 31, 2017, the Group had the following provision and corresponding judicial deposits relating to legal proceedings:

| | Parent Company | | Consolidated | |
|-------------------------------------|-----------------------|-----------------|---------------------|-----------------|
| | Sep-2018 | Dec-2017 | Sep-2018 | Dec-2017 |
| Labor and social security | 20,402 | 24,105 | 20,402 | 24,105 |
| Tax | 611 | 586 | 611 | 586 |
| Civil | 630 | 627 | 630 | 627 |
| | <u>21,643</u> | <u>25,318</u> | <u>21,643</u> | <u>25,318</u> |
| (-) Corresponding judicial deposits | (14,918) | (14,425) | (14,918) | (14,425) |
| Total | <u>6,725</u> | <u>10,893</u> | <u>6,725</u> | <u>10,893</u> |
| Current liabilities | 286 | 2,724 | 286 | 2,724 |
| Non-current liabilities | 6,439 | 8,169 | 6,439 | 8,169 |

Changes in the provision were as follows:

| | Parent Company | | Consolidated | |
|---------------------------------------|-----------------------|-----------------|---------------------|-----------------|
| | Sep-2018 | Dec-2017 | Sep-2018 | Dec-2017 |
| At January 1 | 25,318 | 17,530 | 25,318 | 17,530 |
| Additions of new lawsuits | 12,918 | 14,814 | 12,918 | 14,814 |
| Write-offs | (19,465) | (21,542) | (19,465) | (21,542) |
| Reversals due to changes in lawsuits | (746) | (594) | (746) | (594) |
| Revaluation of amounts ⁽ⁱ⁾ | 1,622 | 12,132 | 1,622 | 12,132 |
| Monetary restatement | 1,996 | 2,978 | 1,996 | 2,978 |
| Closing balance | <u>21,643</u> | <u>25,318</u> | <u>21,643</u> | <u>25,318</u> |

The provision for legal claims took into consideration the best estimate of the amounts involved, for the cases in which the likelihood of loss is estimated as probable by external and internal legal advisors, and a portion of these proceedings is guaranteed by pledged assets (Note 21).

⁽ⁱ⁾ In the first quarter of 2017, there was a revaluation of the amounts related to labor claims with likelihood of loss classified as probable.

Possible losses

At September 30, 2018 and December 31, 2017, the Group was party to legal proceedings of a tax, civil and labor nature, the likelihood of loss in which is estimated as possible by management and its legal advisors, amounting to R\$ 271,198 (R\$ 218,811 - Dec-2017) for the parent company and for the consolidated accounts, of which R\$ 8,373 (R\$ 11 - Dec-2017) corresponds to civil proceedings, R\$ 44,700 (R\$ 35,465 - Dec-2017) to tax proceedings and R\$ 218,125 (R\$ 183,335 - Dec-2017) to labor proceedings.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

Judicial deposits

At September 30, 2018 and December 31, 2017, the Group had the following judicial deposit amounts, for which no corresponding provision had been set up:

| | Parent Company | | Consolidated | |
|---------------------------|-----------------------|-----------------|---------------------|-----------------|
| | Sep-2018 | Dec-2017 | Sep-2018 | Dec-2017 |
| Labor and social security | 18,176 | 12,053 | 18,176 | 12,053 |
| Tax | 11,384 | 12,121 | 11,384 | 12,121 |
| Civil | 3,808 | 5,041 | 3,808 | 5,041 |
| Total | <u>33,368</u> | <u>29,215</u> | <u>33,368</u> | <u>29,215</u> |

Labor contingencies

Labor claims in general relate to lawsuits filed by former employees questioning the payment of unpaid overtime and severance pay. The Group is also involved in proceedings assumed upon the acquisition of Raia S.A., which were filed by former employees of service providers claiming to have employment relationships directly with the Group, or in which the Group received a joint enforcement order for the payment of the labor rights claimed. There are also proceedings filed by professional unions for the payment of union dues, under the dispute regarding the legitimacy of the territorial base.

Tax contingencies

These represent administrative fines, tax rate differences on interstate transfers and tax collection proceedings.

Civil contingencies

The Group is a defendant in lawsuits regarding usual and unique matters arising in the course of its business, most of which seek indemnification for property damage and pain and suffering from consumption relations.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

14. Income tax and social contribution

(a) Income tax and social contribution paid

Effective income tax and social contribution for the quarters are as follow:

| | Parent Company | | Consolidated | |
|---|-------------------------|-------------------------|-------------------------|-------------------------|
| | 3rd Quarter- 2018 | 3rd Quarter- 2017 | 3rd Quarter- 2018 | 3rd Quarter- 2017 |
| Profit before income tax and social contribution | 157,543 | 179,795 | 159,480 | 180,735 |
| Interest on capital | (52,000) | (51,000) | (52,000) | (51,000) |
| Taxable profit | 105,543 | 128,795 | 107,480 | 129,735 |
| Combined tax rate (25% for income tax and 9% for social contribution) | 34% | 34% | 34% | 34% |
| Theoretical tax expense | (35,885) | (43,790) | (36,543) | (44,110) |
| Permanent additions | (2,043) | (574) | (2,083) | (599) |
| Equity in the results of investees | 370 | 180 | | |
| Reduction of taxes due to incentives (P.A.T) | 504 | 551 | 528 | 563 |
| Investment grant (i) | 7,702 | | 7,702 | |
| Other (revaluation reserve + additional income tax exemption ceiling) | (244) | (102) | (247) | (96) |
| Effective income tax and social contribution expense | (29,596) | (43,735) | (30,643) | (44,242) |
| Effective tax rate | 18.8% | 24.3% | 19.2% | 24.5% |

(i) Beginning this quarter, the Company considers as deductible for income tax purposes the gains arising from the ICMS tax benefits in the States of Goiás and Pernambuco, established by supplementary law 160/17, agreement ICMS CONFAZ 190/17, and the amendment to law 12,973/2014. The effect of the adjusted amount on the calculation of IRPJ/CSLL amounted to R\$ 7,702.

(b) Deferred income tax and social contribution

Deferred income tax and social contribution assets amounting to R\$ 51,779 at September 30, 2018 (R\$ 64,732- Dec-2017) for the parent company and R\$ 52,543 at September 30, 2018 (R\$ 65,445 - Dec-2017) for the consolidated accounts arose substantially from temporarily non-deductible expenses that may be carried forward indefinitely, with estimated realization as disclosed in item (c) below.

Deferred income tax and social contribution liabilities amounting to R\$ 306,641 at September 30, 2018 (R\$ 290,949 - Dec-2017) for the parent company and R\$ 309,448 at September 30, 2018 (R\$ 294,160 - Dec- 2017) for the consolidated accounts relate to tax charges on the remaining balances of: (i) the revaluation reserve; and (ii) goodwill from future profitability. Deferred income tax and social contribution refer to:

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

| | Balance sheet | | | | Statement of income | | | |
|--|------------------|------------------|------------------|------------------|---------------------|------------------|------------------|------------------|
| | Parent Company | | Consolidated | | Parent Company | | Consolidated | |
| | Sep-2018 | Dec-2017 | Sep-2018 | Dec-2017 | 3rd Quarter-2018 | 3rd Quarter-2017 | 3rd Quarter-2018 | 3rd Quarter-2017 |
| Revaluation at fair value of land and buildings | (6,998) | (7,066) | (6,998) | (7,066) | | | | |
| Amortization of the goodwill on future profitability | (244,055) | (226,401) | (244,055) | (226,401) | | (10,650) | | (10,650) |
| Non-deductible intangible assets - merger of Raia S.A. | (55,588) | (57,482) | (55,588) | (57,482) | 631 | 631 | 631 | 631 |
| Non-deductible intangible assets – acquisition of 4Bio | | | (2,807) | (3,211) | | | 134 | 134 |
| Adjustment to fair value | 7,290 | 5,877 | 7,290 | 5,877 | 484 | 867 | 484 | 867 |
| Provision for inventory obsolescence | 14,195 | 29,495 | 14,195 | 29,495 | (5,340) | (824) | (5,340) | (824) |
| Provision for sundry obligations | 11,568 | 6,963 | 11,748 | 7,106 | 3,143 | (1,779) | 3,205 | (1,899) |
| Provision for employee profit sharing | 10,383 | 11,472 | 10,697 | 11,778 | (403) | (961) | (395) | (968) |
| Provision for contingencies | 7,359 | 8,609 | 7,359 | 8,609 | (217) | (393) | (217) | (393) |
| Provision for impairment of trade receivables | 984 | 2,316 | 1,254 | 2,580 | 1 | 150 | 92 | 251 |
| Deferred income tax and social contribution expense (benefit) | | | | | (1,701) | (12,959) | (1,406) | (12,851) |
| Deferred tax assets (liabilities), net | (254,862) | (226,217) | (256,905) | (228,715) | | | | |
| Reflected in the balance sheet as follows: | | | | | | | | |
| Deferred tax assets | 51,779 | 64,732 | 52,543 | 65,445 | | | | |
| Deferred tax liabilities | (306,641) | (290,949) | (309,448) | (294,160) | | | | |
| Deferred tax assets (liabilities), net | (254,862) | (226,217) | (256,905) | (228,715) | | | | |
| Reconciliation of deferred tax assets (liabilities), net | Sep-2018 | Dec-2017 | Sep-2018 | Dec-2017 | | | | |
| At the beginning of the period | (226,217) | (189,818) | (228,715) | (193,187) | | | | |
| Taxable revenue recognized in the income statement | (28,712) | (36,496) | (28,257) | (35,625) | | | | |
| Realization of deferred tax recognized in equity | 67 | 97 | 67 | 97 | | | | |
| At the end of the period | (254,862) | (226,217) | (256,905) | (228,715) | | | | |

(c) Estimated recovery of income tax and social contribution credits

The projections of future taxable profits are based on estimates relating to the Group's performance, the behavior of the market in which the Group operates and certain economic aspects, among other factors. Actual amounts may differ from these estimates. According to projections, the tax credit amounting to R\$ 51,779 for the parent company and R\$ 52,543 for the consolidated accounts will be substantially realized in the next 12 months.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

15. Earnings (loss) per share

Basic earnings per share are calculated by dividing the profit attributable to equity holders of the Company by the weighted average number of common shares outstanding during the period. Diluted earnings per share are calculated by adjusting the weighted average number of common shares outstanding to assume conversion of all potential common diluted shares.

The following table presents profit and stock information used for calculating basic and diluted earnings per share:

| | Parent company and consolidated | |
|--|---------------------------------|----------------------|
| | 3rd Quarter- 2018 | 3rd Quarter- 2017 |
| Basic | | |
| Profit for the period | 127,947 | 136,060 |
| Weighted average number of common shares (in thousands) | 329,429 | 329,981 |
| Basic earnings per share - R\$ | 0.38839 | 0.41233 |
| Diluted | | |
| Profit for the period | 127,947 | 136,060 |
| Weighted average number of common shares adjusted for dilution effect (in thousands) | 329,269 | 329,981 |
| Diluted earnings per share - R\$ | 0.38858 | 0.41233 |

16. Equity

(a) Share capital

At September 30, 2018, the fully paid-up capital amounted to R\$ 1,808,639 (R\$ 1,808,639 - Dec-2017), represented by 330,386,000 common registered book-entry shares with no par value, of which 216,615,578 shares were outstanding (211,804,492 common shares - Dec-2017).

Pursuant to the Company's bylaws, it is authorized to increase its capital up to the limit of 400,000,000 common shares, subject to the approval of the Board of Directors.

At September 30, 2018, the Company's ownership interest was as follows:

| | Number of shares | | Interest (%) | |
|--------------------------|--------------------|--------------------|---------------|---------------|
| | Sep-2018 | Dec-2017 | Sep-2018 | Dec-2017 |
| Controlling stockholders | 112,723,850 | 117,907,354 | 34.12 | 35.69 |
| Shares outstanding | 216,615,578 | 211,804,492 | 65.56 | 64.11 |
| Treasury shares | 1,046,572 | 674,154 | 0.32 | 0.20 |
| | <u>330,386,000</u> | <u>330,386,000</u> | <u>100.00</u> | <u>100.00</u> |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

The ownership interest of the controlling stockholders is represented by the families Pipponzi, Pires Oliveira Dias and Galvão and by the Holding Pragma.

The change in the number of shares outstanding of the Company was as follows:

| | <u>Shares outstanding</u> |
|---|--------------------------------------|
| At December 31, 2017 | 211,804,492 |
| (Purchase)/sale of restricted shares, net | <u>4,811,086</u> |
| At September 30, 2018 | <u><u>216,615,578</u></u> |

At September 30, 2018, the Company's common shares were quoted at R\$ 72.43 (closing quote) (R\$ 91.80 at December 31, 2017).

(b) Treasury shares

On August 3, 2017, the Board of Directors authorized the Company to repurchase, over a period of 365 days, its own registered common shares with no par value to be held in treasury and subsequently sold. The changes in treasury shares in the period ended September 30, 2018 are summarized below:

| | <u>Parent Company</u> | |
|--|------------------------------------|------------------------------------|
| | <u>Number of shares</u> | <u>Amount of shares</u> |
| At December 31, 2017 | <u>674,154</u> | <u>12,808</u> |
| Shares delivered to executives related to the 3rd tranche of the 2014 grant 2nd tranche of the 2015 grant and 1st tranche of the 2016 grant | (224,582) | (4,267) |
| Repurchase of shares | <u>597,000</u> | <u>46,925</u> |
| At September 30, 2018 | <u><u>1,046,572</u></u> | <u><u>55,466</u></u> |

At September 30, 2018, the market value of the treasury shares, having as reference the quotation of R\$ 72.43 per share at that date, corresponds to R\$ 75,803.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

(c) Restricted share plan

Since March 2014, the Company offers its officers the Long-Term Incentive Program with Restricted Shares (the "Restricted Share Plan"), which aims to offer an opportunity to receive variable remuneration provided that the officer remains for a predetermined period in the Company.

As stated in the Restricted Share Plan, a portion of their annual variable remuneration (profit-sharing), will be paid to the officer in cash and the remaining balance shall be paid only in Company shares ("incentive stock").

If the officer decides to use a portion of the total amount of the variable remuneration paid in cash to buy Company shares ("own shares") on the stock exchange, the Company will offer the officer an equal number of shares purchased on the stock exchange.

At its discretion, the Company may grant to this officer more Company shares, using as reference the number of own shares acquired by the officer on the stock exchange.

The shares offered to the officer through the Restricted Share Plan may not be sold, assigned or transferred to third parties for a period of four years from the date of the grant, provided that, every year, from the second, third and fourth anniversary of the grant date, the officers will acquire the right to receive a third of their restricted stock.

The changes of the restricted shares are summarized below:

| | Sep-2018 | | Dec-2017 | |
|----------------------------------|------------------|----------------|------------------|----------------|
| | Shares | Amount | Shares | Amount |
| Opening balance | 485,242 | 18,863 | 375,212 | 11,123 |
| Granted shares for the period | 174,362 | 9,287 | 293,260 | 12,603 |
| Delivery of shares in the period | <u>(224,582)</u> | <u>(7,382)</u> | <u>(183,230)</u> | <u>(4,863)</u> |
| Closing balance | <u>435,022</u> | <u>20,768</u> | <u>485,242</u> | <u>18,863</u> |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

17. Net sales revenue

| | Parent Company | | Consolidated | |
|----------------------------|----------------------|----------------------|----------------------|----------------------|
| | 3rd Quarter- 2018 | 3rd Quarter- 2017 | 3rd Quarter- 2018 | 3rd Quarter- 2017 |
| Gross sales revenue | | | | |
| Sales revenue | 3,741,805 | 3,434,277 | 3,941,637 | 3,576,594 |
| Service revenue | 2,985 | 3,416 | 3,040 | 3,431 |
| | <u>3,744,790</u> | <u>3,437,693</u> | <u>3,944,677</u> | <u>3,580,025</u> |
| Taxes on sales | (139,510) | (123,390) | (153,458) | (131,046) |
| Returns, rebates and other | (30,328) | (28,765) | (34,405) | (32,139) |
| Net sales revenue | <u>3,574,952</u> | <u>3,285,538</u> | <u>3,756,814</u> | <u>3,416,840</u> |

Taxes on sales primarily comprise ICMS at rates predominantly between 17% and 18%, for goods not subject to the tax substitute (ST) regime, service tax at 5%, and PIS (1.65%) and COFINS (7.60%) for goods not subject to the one-time taxation regime (Law 10,147/00).

The Company assessed the impacts of IFRS 15/CPC 47 and considering that it operates in the retail industry of medicines and has a single performance obligation and, therefore, there is no complexity involved in defining performance obligations and transferring control of products and services to consumers, as described in Note 4 – Significant accounting policies, it concluded that there are no material impacts related to accounting record in the standard.

18. Information on the nature of expenses recognized in the statement of income

The Group presented its statement of income using a classification based on the function of expenses. Information on the nature of these expenses is recorded in the statement of income as follows:

| | Parent Company | | Consolidated | |
|--|------------------------------|------------------------------|------------------------------|------------------------------|
| | 3rd Quarter- 2018 | 3rd Quarter- 2017 | 3rd Quarter- 2018 | 3rd Quarter- 2017 |
| Personnel expenses | (457,649) | (408,519) | (464,748) | (414,315) |
| Occupancy expenses (i) | (173,899) | (148,951) | (174,491) | (149,471) |
| Service provider expenses | (40,783) | (36,860) | (41,070) | (37,044) |
| Depreciation and amortization (ii) | (104,898) | (86,213) | (105,518) | (86,760) |
| Other (iii) | (135,469) | (117,962) | (141,217) | (123,103) |
| | <u>(912,698)</u> | <u>(798,505)</u> | <u>(927,044)</u> | <u>(810,693)</u> |
| Classified in the statement of income as: | | | | |
| | 3rd Quarter- 2018 | 3rd Quarter- 2017 | 3rd Quarter- 2018 | 3rd Quarter- 2017 |
| Selling expenses | (816,171) | (709,286) | (827,492) | (718,625) |
| General and administrative expenses | (96,527) | (89,219) | (99,552) | (92,068) |
| | <u>(912,698)</u> | <u>(798,505)</u> | <u>(927,044)</u> | <u>(810,693)</u> |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

- (i) These refer to expenses on property rental, condominium fees, electricity, water, communication and Municipal real estate tax (IPTU).
- (ii) Depreciation and amortization totaled R\$ 104,898 in the third quarter of 2018 (R\$ 86,213 - 3rd Quarter-2017) for the parent company, of which R\$ 91,962 (R\$ 76,165 - 3rd Quarter-2017) correspond to the sales area and R\$ 12,936 (R\$ 10,047 - 3rd Quarter-2017) to the administrative area, and R\$ 105,518 (R\$ 86,760 - 3rd Quarter-2017) for the consolidated accounts, of which R\$ 92,089 (R\$ 76,225 - 3rd Quarter-2017) refers to the sales area and R\$ 13,429 (R\$ 10,535 - 3rd Quarter-2017) to the administrative area.
- (iii) These refer mostly to expenses on cards/cash/checks, transportation, materials, other administrative expenses, maintenance of assets, advertising and publicity.

19. Other operating expenses

Refer to non-recurring expenses related to: (i) expenses with consultancy for the preparation of the strategic plan for the following 5 years of R\$ 2,247; (ii) write-off of property and equipment items and intangible assets due to the closure of 4 stores, in the amount of R\$ 1,255.

20. Finance income and costs

(a) Finance income

| | Parent Company | | Consolidated | |
|---|----------------------|----------------------|----------------------|----------------------|
| | 3rd Quarter- 2018 | 3rd Quarter- 2017 | 3rd Quarter- 2018 | 3rd Quarter- 2017 |
| Discounts obtained | 813 | 396 | 820 | 422 |
| Short-term investment yields | 3,612 | 6,893 | 3,612 | 6,893 |
| Interest on intercompany loans | 698 | 899 | | |
| Monetary gains | (651) | 1,106 | (589) | 1,124 |
| Other finance income | 1 | | 52 | 112 |
| Taxes thereon (PIS/COFINS) | (206) | (432) | (206) | (432) |
| Present value adjustment (PVA) - finance income | 14,160 | 18,450 | 15,779 | 20,112 |
| Total finance income | 18,427 | 27,312 | 19,468 | 28,231 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

(b) Finance costs

| | Parent Company | | Consolidated | |
|---|----------------------|----------------------|----------------------|----------------------|
| | 3rd Quarter- 2018 | 3rd Quarter- 2017 | 3rd Quarter- 2018 | 3rd Quarter- 2017 |
| Discounts granted to customers | | | (32) | (7) |
| Interest, charges and bank fees | (166) | (135) | (293) | (189) |
| Charges on debentures | (11,171) | (7,256) | (11,171) | (7,256) |
| Amortization of transaction costs | (160) | (87) | (160) | (87) |
| Charges on borrowings | (4,902) | (11,260) | (4,902) | (11,260) |
| Monetary losses | (458) | (1,467) | (541) | (1,448) |
| Interest on payables - equity interests | (1,426) | (2,551) | (1,426) | (2,551) |
| PVA - finance costs | (26,322) | (33,035) | (27,693) | (34,401) |
| Total finance costs | (44,605) | (55,791) | (46,218) | (57,199) |
| Finance income (costs), net | (26,178) | (28,479) | (26,750) | (28,968) |

21. Guarantees for lawsuits

The following items of property and equipment were given as guarantees for tax, social security and labor proceedings:

| | Parent Company | | Consolidated | |
|--------------------------|----------------|----------|--------------|----------|
| | Sep-2018 | Dec-2017 | Sep-2018 | Dec-2017 |
| Furniture and facilities | 26 | 27 | 26 | 27 |
| Machinery and equipment | 85 | 85 | 85 | 85 |
| | 111 | 112 | 111 | 112 |

22. Lease agreement commitments

The Company and its subsidiary have lease agreements with terms ranging from one to 20 years. Annual lease expenses vary depending on the number of agreements entered into or terminated. Total monthly expenses on these lease agreements (including rental, condominium fees and real estate tax amounted to R\$ 49,192 (R\$ 43,609 - Dec-2017) for the parent company and R\$ 49,343 (R\$ 43,715 - Dec-2017) for the consolidated accounts.

At September 30, 2018 and December 31, 2017, the future minimum payments referring to leases of stores (under cancelable lease agreements) were as follows:

| | Parent Company | | Consolidated | |
|-----------------------|----------------|-----------|--------------|-----------|
| | Sep-2018 | Dec-2017 | Sep-2018 | Dec-2017 |
| From one to 12 months | 524,141 | 447,595 | 525,091 | 448,404 |
| From 13 to 60 months | 1,351,493 | 1,185,782 | 1,353,467 | 1,186,841 |
| Over 60 months | 406,184 | 352,801 | 406,220 | 352,801 |
| | 2,281,818 | 1,986,178 | 2,284,778 | 1,988,046 |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

23. Financial instruments and risk management policy

Financial instruments by category

| | Parent Company | | Consolidated | |
|---|------------------|------------------|------------------|------------------|
| | Sep-2018 | Dec-2017 | Sep-2018 | Dec-2017 |
| Assets | | | | |
| <u>At amortized cost</u> | | | | |
| Cash and cash equivalents (Note 5) | 270,396 | 255,911 | 273,555 | 264,873 |
| Trade receivables (Note 6) | 922,977 | 837,582 | 1,041,121 | 930,071 |
| Other receivables | 168,592 | 158,295 | 169,669 | 120,321 |
| Judicial deposits (Note 13) | 33,368 | 29,215 | 33,368 | 29,215 |
| | <u>1,395,333</u> | <u>1,281,003</u> | <u>1,517,713</u> | <u>1,344,480</u> |
| Total assets | <u>1,395,333</u> | <u>1,281,003</u> | <u>1,517,713</u> | <u>1,344,480</u> |
| Liabilities | | | | |
| <u>Liabilities at fair value through profit or loss</u> | | | | |
| Payables - equity interests (Note 9) | 51,674 | 47,515 | 51,674 | 47,515 |
| | <u>51,674</u> | <u>47,515</u> | <u>51,674</u> | <u>47,515</u> |
| <u>At amortized cost</u> | | | | |
| Trade payables | 1,774,722 | 1,745,041 | 1,862,896 | 1,815,687 |
| Borrowing (Note 12) | 896,718 | 610,959 | 903,126 | 610,959 |
| Other payables | 132,970 | 128,259 | 134,541 | 129,403 |
| | <u>2,804,410</u> | <u>2,484,259</u> | <u>2,900,563</u> | <u>2,556,049</u> |
| Total liabilities | <u>2,856,084</u> | <u>2,531,774</u> | <u>2,952,237</u> | <u>2,603,564</u> |

Financial risk management

The Group's activities expose it to a variety of financial risks: market risk, credit risk and liquidity risk. The Group's risk management program focuses on the unpredictability of financial and operational markets and seeks to minimize potential adverse effects on the Group's financial performance.

The Board of Directors provides principles for overall risk management, as well as written policies covering specific areas, such as interest rate risk, credit risk, use of non-derivative financial instruments and investment of surplus cash.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

(a) Market risk

Foreign exchange risk

All of the asset and liability operations of the Group are denominated in Brazilian reais; therefore, the Company is not exposed to foreign exchange risk.

Most of the BNDES transactions are entered into based on the TJLP + interest and on the SELIC rate. Short-term investments are entered into based on the CDI variations, which does not result in higher interest rate risk since these variations are not significant. Management understands that there is a low risk of significant changes in profit or loss or in cash flows.

(b) Credit risk

Credit risk arises from financial assets, i.e. cash and cash equivalents, short-term investments and trade receivables.

Cash and cash equivalents and short-term investments are maintained with sound financial institutions.

The risk ratings of the cash equivalents, except cash and banks, are in accordance with the main risk rating agencies, according to the table below:

| | Parent Company | | Consolidated | |
|--------------------------------|-----------------------|-----------------|---------------------|-----------------|
| | Sep-2018 | Dec-2017 | Sep-2018 | Dec-2017 |
| Rating - National Scale | | | | |
| brAAA | 187,640 | 17,745 | 190,225 | 26,327 |
| brAA+ | | 65,659 | | 65,659 |
| (*) n/a - Investment Funds | 278 | 90,769 | 278 | 90,769 |
| Total - National Scale | 187,918 | 174,173 | 190,503 | 182,755 |

(*) Not applicable, since there is no risk rating for the Funds.

The granting of credit on sales of goods follows a policy that aims at minimizing defaults. For the quarter ended September 30, 2018, credit sales represented 52% (51% - Dec-2017) for the parent company and 54% (53% - Dec-2017) for the consolidated accounts of which 92% (92% - Dec-2017) for the parent company and 86% (86% - Dec-2017) for the consolidated accounts related to credit card sales which, in the opinion of the Group and based on the history of losses, posed an extremely low risk. The remaining 8% (8% - Dec-2017) for the parent company and 14% (14% - Dec-2017) for the consolidated accounts are credits from PBMs, special plans with companies and post-dated checks and bills for payment that pose a low risk, due to customer selectivity and the adoption of individual limits.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

(c) Liquidity risk

The Group's management continuously monitors forecasts of the Company's liquidity requirements, in order to ensure that it has sufficient cash to meet operational needs. The Group invests its surplus cash in financial assets with appropriate maturities to provide the liquidity necessary to honor its obligations.

(d) Sensitivity analysis

The table below presents a sensitivity analysis of financial instruments that are exposed to losses.

The most probable scenario (scenario I), according to the assessment made by management, is based on a three-month horizon. Two further scenarios are presented, pursuant to CVM Instruction 475/08, in order to show a 25% and 50% deterioration in the risk variables considered (scenarios II and III).

Parent Company

| Operation | Risk | Amount | Scenario I (probable) | Scenario II | Scenario III |
|------------------------------|---------------|---------|--------------------------|-------------|--------------|
| Short-term investments - CDI | 0.5% increase | 187,918 | 940 | 1,174 | 1,409 |
| Revenue | | | 940 | 1,174 | 1,409 |
| REFIS (SELIC) | 0.5% increase | 1,156 | 6 | 7 | 9 |
| Expense | | | 6 | 7 | 9 |

Consolidated

| Operation | Risk | Amount | Scenario I (probable) | Scenario II | Scenario III |
|------------------------------|---------------|---------|--------------------------|-------------|--------------|
| Short-term investments - CDI | 0.5% increase | 190,504 | 953 | 1,190 | 1,428 |
| Revenue | | | 953 | 1,190 | 1,428 |
| REFIS (SELIC) | 0.5% increase | 1,156 | 6 | 7 | 9 |
| Expense | | | 6 | 7 | 9 |

The risk of variations in the TJLP on BNDES operations which could result in material losses for the Group is not considered as probable by management.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

(e) Capital management

The Group's objective relating to capital management is to maintain the Group's investment capacity, thus allowing it to grow its business and provide proper returns for stockholders.

The Group has adopted a policy of not leveraging its capital structure with borrowing, except for long-term credit facilities from BNDES (FINEM) and debentures at interest rates that are commensurate with the Group's profit levels.

Accordingly, this ratio corresponds to the net debt expressed as a percentage of total capital. The net debt, in turn, corresponds to total borrowings less cash and cash equivalents. The total capital is calculated through the sum of the equity, as shown in the individual and consolidated balance sheet, and the net debt, as presented below:

| | <u>Parent Company</u> | | <u>Consolidated</u> | |
|---|-----------------------|------------------|---------------------|------------------|
| | <u>Sep-2018</u> | <u>Dec-2017</u> | <u>Sep-2018</u> | <u>Dec-2017</u> |
| Short - and long-term borrowings | 896,718 | 610,959 | 903,126 | 610,959 |
| (-) Cash and cash equivalents | (270,396) | (255,911) | (273,555) | (264,873) |
| Net debt | <u>626,322</u> | <u>355,048</u> | <u>629,571</u> | <u>346,086</u> |
| Equity attributable to the stockholders of the parent company | 3,364,388 | 3,222,513 | 3,364,388 | 3,222,513 |
| Non-controlling interest | | | 30,467 | 27,859 |
| Total equity | <u>3,364,388</u> | <u>3,222,513</u> | <u>3,394,855</u> | <u>3,250,372</u> |
| Total capital | <u>3,990,710</u> | <u>3,577,561</u> | <u>4,024,426</u> | <u>3,596,458</u> |
| Gearing ratio - % | <u>15.69</u> | <u>9.92</u> | <u>15.64</u> | <u>9.62</u> |

The increase in the financial leverage ratio at September 30, 2018 was mainly due to the issuance of debentures (Note 12) and consequent use of funds obtained in the Company's investments and operations.

(f) Fair value estimation

The carrying values of financial investments in the balance sheet approximate their fair values since the remuneration rates are based on the CDI variation. The carrying values of trade receivables and payables are measured at amortized cost and are recorded at their original amount, less the provision for impairment and adjustment to present value, when applicable. The carrying values are assumed to approximate their fair values, taking into consideration the realization of these balances and settlement terms not exceeding 60 days.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

Borrowings are classified as financial liabilities not measured at fair value and are carried at amortized cost and according to contractual conditions. The fair values of the borrowings approximate their carrying values since they refer to financial instruments with rate that approximate market rates. The estimated fair values are as follows:

| | Parent Company | | | | Consolidated | | | |
|------------|-----------------|----------------|----------------|----------------|-----------------|----------------|----------------|----------------|
| | Carrying amount | | Fair value | | Carrying amount | | Fair value | |
| | Sep-2018 | Dec-2017 | Sep-2018 | Dec-2017 | Sep-2018 | Dec-2017 | Sep-2018 | Dec-2017 |
| BNDES | 211,486 | 307,803 | 211,483 | 307,811 | 211,486 | 307,803 | 211,483 | 307,811 |
| Debentures | 685,232 | 303,156 | 685,213 | 303,145 | 685,232 | 303,156 | 685,213 | 303,145 |
| Other | | | | | 6,408 | | 6,408 | |
| | <u>896,718</u> | <u>610,959</u> | <u>896,696</u> | <u>610,956</u> | <u>903,126</u> | <u>610,959</u> | <u>903,104</u> | <u>610,956</u> |

For disclosure purposes, the fair value of financial liabilities is estimated by discounting future contractual cash flow at the interest rates available in the market that are available to the Group for similar financial instruments. The effective interest rates at the balance sheet dates are usual market rates and their fair value does not significantly differ from the balances in the accounting records.

At September 30, 2018, the Group had no material assets and liabilities measured at fair value at Level 1 and Level 2 in the fair value hierarchy. The following table presents the changes in Level 3 instruments for the period ended September 30, 2018:

| | Parent company and consolidated | |
|---|---------------------------------|---------------|
| | Sep-2018 | Sep-2017 |
| Payables - equity interests | | |
| At January 1 | 47,515 | 45,228 |
| Expenses recognized in the statement of income: | 4,159 | 7,287 |
| At September 30 | <u>51,674</u> | <u>52,515</u> |
| Changes in unrealized expenses for the period included in the statement of income | <u>4,159</u> | <u>7,287</u> |

24. Derivative financial instruments

The Group does not operate with derivative instruments, except in specific situations. At September 30, 2018 and December 31, 2017, the Group did not have any derivative transactions.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

25. Transactions with related parties

(a) Transactions with related parties consist of transactions with the Company's stockholders and persons connected to them:

| | Relationship | Parent Company | | Consolidated | | Parent Company | | Consolidated | |
|---|-----------------------------|----------------|---------------|--------------|------------|--------------------|------------------|------------------|------------------|
| | | Current assets | | | | Transaction amount | | | |
| | | Sep-2018 | Dec-2017 | Sep-2018 | Dec-2017 | 3rd Quarter-2018 | 3rd Quarter-2017 | 3rd Quarter-2018 | 3rd Quarter-2017 |
| Receivables | | | | | | | | | |
| Special plans (i) | | | | | | | | | |
| Regimar Comercial S.A. | Stockholder/Family | 12 | 12 | 12 | 12 | 28 | 30 | 28 | 30 |
| Heliomar Ltda. | Stockholder/Board Member | | | | | 2 | 2 | 2 | 2 |
| Rodrigo Wright Pipponzi (Editora Mol Ltda.) | Stockholder/Family | 1 | | 1 | | 1 | 3 | 1 | 3 |
| | | <u>13</u> | <u>12</u> | <u>13</u> | <u>12</u> | <u>31</u> | <u>35</u> | <u>31</u> | <u>35</u> |
| Other receivables | | | | | | | | | |
| Commercial agreements | | | | | | | | | |
| Natura Cosméticos S.A. (ii) | Stockholder / Related party | 90 | 123 | 90 | 123 | 180 | 114 | 180 | 114 |
| Advances to suppliers | | | | | | | | | |
| Cfly Consultoria e Gestão Empresarial Ltda. (iii) | Family | 847 | 440 | 847 | 440 | | | | |
| Zurcher, Ribeiro Filho, Pires Oliveira Dias e Freire – Advogados (iv) | Stockholder/Family | 50 | 50 | 50 | 50 | | | | |
| Loan and other receivables 4Bio Medicamentos S.A. (v) | | | | | | | | | |
| 4Bio Medicamentos S.A. (v) | Subsidiary | 40,704 | 38,831 | | | 805 | 966 | | |
| | | <u>41,691</u> | <u>39,444</u> | <u>987</u> | <u>613</u> | <u>985</u> | <u>1,080</u> | <u>180</u> | <u>114</u> |
| | | <u>41,704</u> | <u>39,456</u> | <u>1,000</u> | <u>625</u> | <u>1,016</u> | <u>1,115</u> | <u>211</u> | <u>149</u> |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

| | Relationship | Parent Company | | Consolidated | | Parent Company | | Consolidated | |
|---|--------------------------------------|---------------------|--------------|--------------|--------------|--------------------|------------------|------------------|------------------|
| | | Current liabilities | | | | Transaction amount | | | |
| | | Sep-2018 | Dec-2017 | Sep-2018 | Dec-2017 | 3rd Quarter-2018 | 3rd Quarter-2017 | 3rd Quarter-2018 | 3rd Quarter-2017 |
| Payables | | | | | | | | | |
| Rentals (ii) | | | | | | | | | |
| Heliomar Ltda. | Stockholder/Board Member | 19 | 19 | 19 | 19 | 56 | 56 | 56 | 56 |
| Antonio Carlos Pipponzi | Stockholder/Board Member | 7 | 7 | 7 | 7 | 23 | 23 | 23 | 23 |
| Rosalia Pipponzi Raia | Stockholder/Board Member | 7 | 7 | 7 | 7 | 23 | 23 | 23 | 23 |
| Estate of Franco Maria David Pietro | Stockholder/Board Member | | | | | | | | |
| Pipponzi | | 7 | 7 | 7 | 7 | 23 | 23 | 23 | 23 |
| | | <u>40</u> | <u>40</u> | <u>40</u> | <u>40</u> | <u>125</u> | <u>125</u> | <u>125</u> | <u>125</u> |
| Services contracted | | | | | | | | | |
| Zurcher, Ribeiro Filho, Pires Oliveira Dias e Freire Advogados (iv) | Stockholder/Family | 47 | 49 | 47 | 49 | 1,968 | 1,645 | 1,968 | 1,645 |
| Rodrigo Wright Pipponzi (Editora Mol Ltda.) (vii) | Stockholder/Family | 678 | 869 | 678 | 869 | 2,604 | 2,019 | 2,604 | 2,019 |
| Cfly Consultoria e Gestão Empresarial Ltda. (iii) | Family | 178 | | 178 | | 711 | 45 | 711 | 45 |
| FMA Assessoria e Consultoria (viii) | Stockholder / Alternate Board Member | | | | | 30 | | 30 | |
| | | <u>903</u> | <u>918</u> | <u>903</u> | <u>918</u> | <u>5,313</u> | <u>3,709</u> | <u>5,313</u> | <u>3,709</u> |
| Purchase of goods | | | | | | | | | |
| Natura Cosméticos S.A. (ii) | Stockholder / Related party | 561 | 1,221 | 561 | 1,221 | 866 | 951 | 866 | 951 |
| | | <u>561</u> | <u>1,221</u> | <u>561</u> | <u>1,221</u> | <u>866</u> | <u>951</u> | <u>866</u> | <u>951</u> |
| | | <u>1,504</u> | <u>2,179</u> | <u>1,504</u> | <u>2,179</u> | <u>6,304</u> | <u>4,785</u> | <u>6,304</u> | <u>4,785</u> |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

- (i) Refer to sales made by agreements whose transactions are executed into under commercial conditions equivalent to those practiced with other companies.
- (ii) Purchase and sale of Natura Cosméticos S.A.'s products, which will be sold across the national territory and Raia Drogasil will receive a percentage on the products sold. Some members of the controlling block of Natura Cosméticos S.A. indirectly own shares of Raia Drogasil S.A.
- (iii) Provision of services of aircraft operation to the owner Raia Drogasil S.A., which will pay the operator a monthly remuneration for the services of Operational Advisory, Compliance, Finance, Maintenance Coordination and Maintenance Technical Control.
- (iv) Transactions related to legal advisory.
- (v) During 2016 and 2017, loan transactions between Raia Drogasil S.A. (Lender) and 4Bio Medicamentos S.A. (Borrower) were carried out in the amounts of R\$ 14,000 and R\$ 20,100, respectively. All loan agreements are monetarily restated by 110% of the CDI and mature in December 2018.

Other receivables comprise commissions on Raia Drogasil referrals (R\$ 36).

- (vi) Transactions related to rental of commercial properties for the implementation of stores.
- (vii) These balances and transactions relate to service agreements for the preparation, creation and production of publicity materials for the institutional sales area and the design of the Company's monthly internal magazine.
- (viii) Transactions related to sales representation services with trade associations.

Moreover, we inform that there are no additional transactions other than the amounts presented above and that the category of the related parties corresponds to the entity's key management personnel.

(b) Key management compensation

Key management includes the Officers, Directors and members of the Supervisory Board. The compensation paid or payable for services rendered is as follows:

| | Parent Company | | Consolidated | |
|----------------------------|----------------------|----------------------|----------------------|----------------------|
| | 3rd Quarter- 2018 | 3rd Quarter- 2017 | 3rd Quarter- 2018 | 3rd Quarter- 2017 |
| Fees and social charges | 4,203 | 3,597 | 4,642 | 4,018 |
| Bonuses and social charges | 4,636 | 5,717 | 4,735 | 5,784 |
| Fringe benefits | 111 | 112 | 111 | 112 |
| | <u>8,950</u> | <u>9,426</u> | <u>9,488</u> | <u>9,914</u> |

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Notes to the Quarterly Information

All amounts in thousands of reais unless otherwise stated

26. Insurance coverage

The Group has adopted a policy of taking out insurance coverage at amounts deemed sufficient to cover any losses on assets or civil liability attributed to it taking into consideration the nature of its activities and the guidance of its insurance consultants.

The Group had the following insurance coverage at September 30, 2018:

| | Parent Company | | Consolidated | |
|-----------------------|-----------------------|-----------------|---------------------|-----------------|
| | Sep-2018 | Dec-2017 | Sep-2018 | Dec-2017 |
| Inventory loss risks | 184,437 | 150,197 | 219,825 | 170,825 |
| Permanent assets | 287,491 | 232,862 | 294,631 | 238,682 |
| Loss of profits | 242,556 | 237,873 | 293,670 | 262,052 |
| Civil liability risks | 38,424 | 33,602 | 40,000 | 34,500 |
| | <u>752,908</u> | <u>654,534</u> | <u>848,126</u> | <u>706,059</u> |

27. Non-cash transactions

At September 30, 2018, the main transactions that did not involve the Group's cash were:

- (i) the restatement of the financial liability arising from the payables to Subsidiary 4Bio (Note 9);
- (ii) part of the compensation of key management personnel associated with the restricted share plan (Note 25); and
- (iii) the installment purchase of property and equipment items in the amount of R\$ 16,256 (R\$ 11,793 - Dec-2017).

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Comment on the Behavior of Business Projections

In this section, in accordance with CVM Instruction 480/09, we compare the projections of store openings with the data on the store openings every year, through the end of the current year. The projections for 2016 and 2017 were disclosed to the market on July 28, 2016, while the projections for 2018 and 2019 were disclosed on November 9, 2017.

| YEAR | PRIOR PROJECTION | CURRENT PROJECTION | ACTUAL ACCUMULATED¹ |
|-------------|-------------------------|---------------------------|---------------------------------------|
| 2016 | 165 openings | 200 openings | 212 openings |
| 2017 | 195 openings | 200 openings | 210 openings |
| 2018 | | 240 openings | 173 openings |
| 2019 | | 240 openings | |

¹ For 2018, accumulated until 9/30/2018.

On July 28, 2016, we revised our prior projection of 165 store openings in 2016 and 195 store openings in 2017 to 200 store openings for both years. The Company ended 2017 with 210 store openings and reiterates the projection of 240 openings for 2018 and 2019.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Reports and Statements / Report on Special Review - Without Exceptions

Report on review of quarterly information

To the Board of Directors and Stockholders
Raia Drogasil S.A.

Introduction

We have reviewed the accompanying parent company and consolidated interim accounting information of Raia Drogasil S.A. ("Company"), included in the Quarterly Information Form (ITR) for the quarter ended September 30, 2018, comprising the balance sheet at that date and the statements of income and comprehensive income for the quarter and nine-month period then ended, and the statements of changes in equity and cash flows for the nine-month period then ended, and a summary of significant accounting policies and other explanatory information.

Management is responsible for the preparation of the parent company and consolidated interim accounting information in accordance with the accounting standard CPC 21 - "Interim Financial Reporting", of the Brazilian Accounting Pronouncements Committee (CPC) and International Accounting Standard (IAS) 34 - "Interim Financial Reporting" issued by the International Accounting Standards Board (IASB), as well as the presentation of this information in accordance with the standards issued by the Brazilian Securities Commission (CVM), applicable to the preparation of the Quarterly Information (ITR). Our responsibility is to express a conclusion on this interim accounting information based on our review.

Scope of review

We conducted our review in accordance with Brazilian and International Standards on Reviews of Interim Financial Information (NBC TR 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" and ISRE 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", respectively). A review of interim information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Brazilian and International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion on the interim information

Based on our review, nothing has come to our attention that causes us to believe that the accompanying parent company and consolidated interim accounting information included in the quarterly information referred to above has not been prepared, in all material respects, in accordance with CPC 21 and IAS 34 applicable to the preparation of the Quarterly Information, and presented in accordance with the standards issued by the CVM.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Reports and Statements / Report on Special Review - Without Exceptions

Other matters

Statements of value added

We have also reviewed the parent company and consolidated statements of value added for the nine-month period ended September 30, 2018. These statements are the responsibility of the Company's management, and are required to be presented in accordance with standards issued by the CVM applicable to the preparation of Quarterly Information (ITR) and are considered supplementary information under IFRS, which do not require the presentation of the statement of value added. These statements have been submitted to the same review procedures described above and, based on our review, nothing has come to our attention that causes us to believe that they have not been prepared, in all material respects, in a manner consistent with the parent company and consolidated interim accounting information taken as a whole.

São Paulo, October 30, 2018

PricewaterhouseCoopers
Auditores Independentes
CRC 2SP000160/O-5

Renato Barbosa Postal
Contador CRC 1SP187382/O-0

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Opinions and Representations / Opinion of Supervisory Board or Equivalent Body

To the Board of Directors and Stockholders of Raia Drogasil S.A.

The Company's Supervisory Board, in exercising its duties and legal responsibilities, has examined the Quarterly Information (ITR) for the quarter ended September 30, 2018 and, based on the examinations performed and on clarifications provided by management, and also considering the favorable Report on Special Review without exceptions, issued by the independent auditor PricewaterhouseCoopers Auditores Independentes, the Supervisory Board members concluded that the documents above are fairly presented, in all material respects.

São Paulo, October 30, 2018.

Gilberto Lério
Supervisory Board member

Fernando Carvalho Braga
Supervisory Board member

Mário Antonio Luiz Corrêa
Supervisory Board member

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Opinions and Representations / Officers' Representation on Financial Statements

RAIA DROGASIL S.A.

In accordance with article 25, paragraph 1, items V and VI, of CVM Instruction 480/09, the Company's officers represent that they have reviewed, discussed and agree with the conclusions expressed in the quarterly information (ITR) for the quarter ended September 30, 2018.

São Paulo, October 30, 2018.

Marcilio D'Amico Pousada
Chief Executive Officer

Fernando Kozel Varela
Officer

Antonio Carlos Coelho
Officer

Renato Cepollina Raduan
Officer

Eugênio De Zagottis
Officer

Maria Susana de Souza
Officer

Marcello De Zagottis
Officer

Antonio Carlos Marques de Oliveira
Accountant in charge CRC-1SP215445/O-0

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 9/30/2018 - RAIA DROGASIL S.A.

Opinions and Representations / Officers' Representation on Independent Auditor's Report

RAIA DROGASIL S.A.

In accordance with article 25, paragraph 1, items V and VI, of CVM Instruction 480/09, the Company's officers represent that they have reviewed, discussed and agree with the Quarterly Information (ITR) for the quarter ended September 30, 2018.

São Paulo, October 30, 2018.

Marcelio D'Amico Pousada
Chief Executive Officer

Fernando Kozel Varela
Officer

Antonio Carlos Coelho
Officer

Renato Cepollina Raduan
Officer

Eugênio De Zagottis
Officer

Maria Susana de Souza
Officer

Marcello De Zagottis
Officer

Antonio Carlos Marques de Oliveira
Accountant in charge CRC-1SP215445/O-0